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A B S T R A C T
Background
Hypertensive disorders in pregnancy are significant contributors to maternal and perinatal morbidity and mortality. These disorders
include well-controlled chronic hypertension, gestational hypertension (pregnancy-induced hypertension) andmild pre-eclampsia. The
definitive treatment for these disorders is planned early delivery and the alternative is to manage the pregnancy expectantly if severe
uncontrolled hypertension is not present, with close maternal and fetal monitoring. There are benefits and risks associated with both,
so it is important to establish the safest option.
Objectives
To assess the benefits and risks of a policy of planned early delivery versus a policy of expectant management in pregnant women with
hypertensive disorders, at or near term (from 34 weeks onwards).
Search methods
We searched Cochrane Pregnancy and Childbirth Trials Register (12 January 2016) and reference lists of retrieved studies.
Selection criteria
Randomised trials of a policy of planned early delivery (by induction of labour or by caesarean section) compared with a policy of
delayed delivery (“expectant management”) for women with hypertensive disorders from 34 weeks’ gestation. Cluster-randomised trials
would have been eligible for inclusion in this review, but we found none.
Studies using a quasi-randomised design are not eligible for inclusion in this review. Similarly, studies using a cross-over design are not
eligible for inclusion, because they are not a suitable study design for investigating hypertensive disorders in pregnancy.
Data collection and analysis
Two review authors independently assessed eligibility and risks of bias. Two review authors independently extracted data. Data were
checked for accuracy.
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Main results
We included five studies (involving 1819 women) in this review.
There was a lower risk of composite maternal mortality and severe morbidity for women randomised to receive planned early delivery
(risk ratio (RR) 0.69, 95% confidence interval (CI) 0.57 to 0.83, two studies, 1459 women (evidence graded high)). There were no clear
differences between subgroups based on our subgroup analysis by gestational age, gestational week or condition. Planned early delivery
was associated with lower risk of HELLP syndrome (RR 0.40, 95% CI 0.17 to 0.93, 1628 women; three studies) and severe renal
impairment (RR 0.36, 95% CI 0.14 to 0.92, 100 women, one study).
There was not enough information to draw any conclusions about the effects on composite infant mortality and severe morbidity.
We observed a high level of heterogeneity between the two studies in this analysis (two studies, 1459 infants, I2 = 87%, Tau2 = 0.98), so
we did not pool data in meta-analysis. There were no clear differences between subgroups based on our subgroup analysis by gestational
age, gestational week or condition. Planned early delivery was associated with higher levels of respiratory distress syndrome (RR 2.24,
95% CI 1.20 to 4.18, three studies, 1511 infants), and NICU admission (RR 1.65, 95% CI 1.13 to 2.40, four studies, 1585 infants).
There was no clear difference between groups for caesarean section (RR 0.91, 95% CI 0.78 to 1.07, 1728 women, four studies,
evidence graded moderate), or in the duration of hospital stay for the mother after delivery of the baby (mean difference (MD) -0.16
days, 95% CI -0.46 to 0.15, two studies, 925 women, evidence graded moderate) or for the baby (MD -0.20 days, 95% CI -0.57 to
0.17, one study, 756 infants, evidence graded moderate).
Two fairly large, well-designed trials with overall low risk of bias contributed the majority of the evidence. Other studies were at low or
unclear risk of bias. No studies attempted to blind participants or clinicians to group allocation, potentially introducing bias as women
and staff would have been aware of the intervention and this may have affected aspects of care and decision-making.
The level of evidence was graded high (composite maternal mortality and morbidity), moderate (caesarean section, duration of hospital
stay after delivery for mother, and duration of hospital stay after delivery for baby) or low (composite infant mortality and morbidity).
Where the evidence was downgraded, it was mostly because the confidence intervals were wide, crossing both the line of no effect and
appreciable benefit or harm.
Authors’ conclusions
For women suffering from hypertensive disorders of pregnancy after 34 weeks, planned early delivery is associated with less composite
maternal morbidity and mortality. There is no clear difference in the composite outcome of infant mortality and severe morbidity;
however, this is based on limited data (from two trials) assessing all hypertensive disorders as one group.
Further studies are needed to look at the different types of hypertensive diseases and the optimal timing of delivery for these conditions.
These studies should also include infant and maternal morbidity and mortality outcomes, caesarean section, duration of hospital stay
after delivery for mother and duration of hospital stay after delivery for baby.
An individual patient meta-analysis on the data currently available would provide further information on the outcomes of the different
types of hypertensive disease encountered in pregnancy.
P L A I N L A N G U A G E S U M M A R Y
Is it safer to deliver a baby immediately or wait if the mother has high blood pressure after 34 weeks of pregnancy that is not
persistently severe?
What is the issue?
Women who have high blood pressure (hypertension) during pregnancy or who develop pre-eclampsia (high blood pressure with
protein in the urine or other organ systems involvement, or both) can develop serious complications. Potential complications for the
mother are worsening of pre-eclampsia, development of seizures and eclampsia, HELLP syndrome (haemolysis, elevated liver enzymes
and low platelet count), detachment of the placenta, liver failure, renal failure, and difficulty breathing because of fluid in the lungs.
Delivering the baby usually stops the mother’s high blood pressure from getting worse, but a baby who is born prematurely may have
other health problems, such as difficulty breathing, because the lungs are still immature. Induction of labour can lead to overstimulation
of contractions and fetal distress. The alternative is waiting to deliver the baby while closely monitoring both the mother and her baby.
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Why is this important?
As there are both benefits and risks to planned early delivery compared with waiting when the mother has high blood pressure toward
the end of pregnancy, we wanted to know which is the safest option. We looked for clinical trials that compared planned early delivery,
by induction of labour or by caesarean section, with a policy of delayed delivery of the baby.
What evidence did we find?
We searched for evidence on 12 January 2016 and found five randomised studies, involving 1819 women. Two of the studies were
large, high-quality studies, in women with gestational hypertension, mild pre-eclampsia or deteriorating existing hypertension at 34
to 37 weeks (704 women) or with gestational hypertension or mild pre-eclampsia at 36 to 41 weeks (756 women). Fewer women
who received planned early delivery experienced severe adverse outcomes (1459 women, high-quality evidence). There was not enough
information to draw any conclusions about the effects on the number of babies born with poor health, with a high level of variability
between the two studies (1459 infants, low-quality evidence). There was no clear difference between planned early delivery and delayed
delivery for the number of caesarean sections (four studies, 1728 women, moderate-quality evidence), or the duration of the mother’s
hospital stay after the birth of the baby (two studies, 925 women, moderate-quality evidence) (or for the baby (one study, 756 infants,
moderate-quality evidence)). More babies who were delivered early had breathing problems (respiratory distress syndrome, three studies,
1511 infants), or were admitted to the neonatal unit (four studies, 1585 infants). Fewer women who delivered early developed HELLP
syndrome (three studies, 1628 women) or severe kidney problems (one study, 100 women).
Two studies compared women who had labour induced at 34 to 36 weeks and at 34 to 37 weeks with a comparison group who were
monitored until 37 weeks, when induction was begun if labour had not started spontaneously. Three studies compared induction of
labour at term or closer to term, at 37 completed weeks and at 36 to 41 weeks, with women who were monitored until 41 weeks
when induction was begun if labour had not started spontaneously. Other inclusion and exclusion criteria also differed between the
five studies.
No studies attempted to blind the women or their clinicians towhich group theywere in.Women and staff were aware of the intervention
and this may have affected aspects of care and decision-making. Most of the evidence was of moderate quality, so we can be moderately
certain about the findings.
What does this mean?
Overall, if a woman’s baby was delivered immediately after 34 weeks, there was less risk of a complication for the mother and no clear
difference in the overall rate of complications for the baby, but information was limited.
These findings are applicable to general obstetric practice when high blood pressure disorders during pregnancy are considered together.
Further studies are needed to look at the different types of hypertensive disorders individually.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Planned early delivery versus expectant management for hypertensive disorders f rom 34 weeks’ gestat ion to term
Patient or population: pregnant women with hypertensive disorders f rom 34 weeks’ gestat ion to term
Setting: 2 studies in the Netherlands, 1 in India, and 1 in the USA
Intervention: planned early delivery
Comparison: expectant management
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with GRADE
Composite maternal
mortality and morbidity
Study populat ion RR 0.69
(0.57 to 0.83)
1459
(2 RCTs)
⊕⊕⊕⊕
HIGH
242 per 1000 167 per 1000
(138 to 201)
Moderate
235 per 1000 162 per 1000
(134 to 195)
Composite infant mor-
tality and morbidity
not pooled 1459
(2 RCTs)
This outcome was not
pooled, due to substan-
t ial stat ist ical hetero-
geneity (I2 = 87%, Tau2
= 0.98)
Caesarean sect ion Study populat ion RR 0.91
(0.78 to 1.07)
1728
(4 RCTs)
⊕⊕⊕©
MODERATE 1
267 per 1000 243 per 1000
(208 to 285)
Moderate
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302 per 1000 275 per 1000
(236 to 324)
Durat ion of hospital
stay af ter delivery for
mother (days)
The mean durat ion of
hospital stay af ter de-
livery for mother (days)
was 0
The mean durat ion of
hospital stay af ter deliv-
ery for mother (days) in
the intervent ion group
was 0.16 fewer (0.46
fewer to 0.15 more)
- 925
(2 RCTs)
⊕⊕⊕©
MODERATE 1
Durat ion of hospital
stay af ter delivery for
baby (days)
The mean durat ion of
hospital stay af ter deliv-
ery for baby (days) was
0
The mean durat ion of
hospital stay af ter de-
livery for baby (days) in
the intervent ion group
was 0.2 days fewer (0.
57 fewer to 0.17 more)
- 756
(1 RCT)
⊕⊕⊕©
MODERATE 1
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Wide conf idence interval crossing the line of no ef fect.
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B A C K G R O U N D
Description of the condition
Hypertensive disorders in pregnancy are significant contributors
to maternal and perinatal morbidity and mortality in low-, mid-
dle- and high-income countries (Khan 2006). They occur in up to
10% of all pregnancies (Dolea 2003; Saftlas 1990; Steegers 2010)
and in up to 11% of first pregnancies (Villar 2003). There is wide
variation in the incidence betweendifferent countries, and regional
differences may exist (Abalos 2013). This may be explained by
differences in maternal age distribution, the proportion of primi-
parous women among the populations (Hutcheon 2011), and di-
etary differences such as low-calcium intake (Belizan 1980) and
genetic characteristics.
There are a number of classification systems for the hypertensive
disorders of pregnancy. The most recent classification system that
has been published is from the International Society for the Study
of Hypertensive Disorders in Pregnancy (ISSHP) (Magee 2014).
Other commonly-used classification systems are the National In-
stitute for Health and Clinical Excellence (NICE) classification
system (NICE 2010), which is currently under review, and the
American College of Obstetricians and Gyneologists classification
of Hypertensive disorders in pregnancy (ACOG Hypertension in
Pregnancy 2013).
The ISSHP classification
Hypertension in pregnancy: office or in-hospital systolic blood
pressure (BP) greater thanor equal to 140mmHgand/or a diastolic
blood pressure greater than or equal to 90mmHg on the average of
at least two measurements, taken at least 15 minutes apart, using
the same arm.
Severe hypertension: systolic blood pressure greater than or equal
to 160 mmHg or a diastolic blood pressure greater than or equal
to 110 mmHg on the average of at least two measurements, taken
at least 15 minutes apart, using the same arm.
Pre-existing (chronic) hypertension: hypertension that predates
the pregnancy or appears before 20 weeks’ gestation.
Gestational hypertension: hypertension that appears at or after
20 weeks of gestation.
Pre-eclampsia: gestational hypertension and new proteinuria or
one or more adverse conditions or one or more serious complica-
tions (see Table 3 for definitions of adverse conditions and serious
complications).
In this classification an adverse condition consists of maternal
symptoms, signs, abnormal laboratory results and abnormal fetal
monitoring that may herald the development of severe maternal
or fetal complications and significant proteinuria is a value greater
than or equal to 0.3 g/d in a complete 24-hour urine collection
or a spot (random) urine sample with greater than or equal to 30
mg/mmol urinary creatinine.
Severe pre-eclampsia: pre-eclampsia associatedwith a severe com-
plication that warrants delivery regardless of gestational age.
NICE classification
Pre-existing/chronic hypertension: hypertension defined as a
systolic blood pressure above 140 mmHg or diastolic blood pres-
sure above 90 mmHg prior to pregnancy or hypertension present-
ing in the first 20 weeks of pregnancy, (on at least two occasions)
or hypertension persisting until at least 12 weeks postpartum or
if the woman is already taking antihypertensive medication when
referred to maternity services. It can be primary (essential hyper-
tension) or secondary (to various medical conditions) in aetiology.
Gestational hypertension: elevated blood pressure (systolic blood
pressure above 140 mmHg and diastolic blood pressure above
90 mmHg measured on two occasions at least four hours apart)
in previously normotensive pregnant women presenting after 20
weeks of pregnancy without proteinuria.
Severe gestational hypertension: elevated systolic blood pressure
of more than 160 mmHg and/or diastolic blood pressure of more
than 110 mmHg at least four hours apart.
The diagnosis of gestational hypertension is temporary and be-
comes pre-eclampsia if proteinuria develops, or chronic hyperten-
sion if blood pressure is still elevated at 12 weeks postpartum, or
transient hypertension of pregnancy if the blood pressure is normal
at 12 weeks postpartum (Magloire 2012). About 15% to 25% of
women with gestational hypertension will develop pre-eclampsia
(Davis 2007). This may increase up to 46% the earlier the diag-
nosis of gestational hypertension is made (Barton 2001).
Pre-eclampsia: hypertension (systolic blood pressure above 140
mmHg and diastolic blood pressure above 90 mmHg) measured
on two occasions at least four hours apart presenting after 20
weeks with significant proteinuria (urinary protein: creatinine ra-
tio greater than 30 mg/mmol or more than 0.3 g in a validated
24-hour urine specimen).
Severe pre-eclampsia: pre-eclampsia with severe hypertension
(systolic blood pressure above 160 mmHg and/or diastolic blood
pressure above 110 mmHg) or other signs/symptoms such as
symptoms of central nervous system dysfunction, liver capsule
distension, liver impairment, thrombocytopenia (decrease in the
number of platelets), severe proteinuria of more than 3 g in 24
hours or 3+ on dipstick, renal impairment, oliguria (less than 500
mL in 24 hours), pulmonary oedema, intrauterine growth restric-
tion or reduced liquor volume (Duley 2009).
Pre-eclampsia superimposed on pre-existing hypertension:
new onset of proteinuria after 20 weeks of pregnancy in a woman
with pre-existing hypertension. In cases where proteinuria is
present in early pregnancy, pre-eclampsia is defined as worsening
of hypertension or development of symptoms/signs of severe pre-
eclampsia (August 2012).
Complications of hypertensive disorders during pregnancy are as-
sociatedwith worsening of pre-eclampsia, development of eclamp-
sia, HELLP syndrome (haemolysis, elevated liver enzymes and low
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platelet count), placental abruption, liver failure, renal failure, pul-
monary oedema, and maternal death (Sibai 2005).
ACOG Hypertension in Pregnancy Classification
Pre-eclampsia: Blood pressure greater than or equal to 140
mmHG systolic or greater than or equal to 90 mmHg diastolic
on two occasions at least 4 hours apart after 20 weeks of gestation
in a woman with a previously normal blood pressure OR a blood
pressure greater than or equal to 160 mmHg systolic or greater
than or equal to 110 mm Hg diastolic, confirmed within a short
interval to facilitate timely antihypertensive therapy with protein-
uria, defined as greater than or equal to 300 mg per 24-hour urine
collection or a protein/creatinine ratio greater than or equal to 0.3
mg/dL or a dipstick reading of 1+ if other quantitative methods
are not available or in the absence of proteinuria, new onset hy-
pertension with thrombocytopaenia, renal insufficiency, impaired
liver function, pulmonary oedema or cerebral or visual symptoms.
Chronic hypertension: High blood pressure known to predate
conception or detected before 20 weeks of gestation.
Chronic hypertension with superimposed pre-eclampsia: In-
clude the following scenarios:
1. Women with hypertension only in early gestation who develop
proteinuria after 20 weeks of gestation.
2.Womenwith hypertension andproteinuria before 20weekswho
develop a sudden exacerbation of hypertension, suddenlymanifest
other signs and symptoms such as an increase in liver enzymes,
present with thrombocytopaenia,manifest with symptoms of right
upper quadrant pain and severe headaches, develop pulmonary
oedema or congestion, develop renal insufficiency or have sudden
substantial sustained increases in protein excretion.
Gestational hypertension: New onset hypertension after 20
weeks gestation in the absence of accompanying proteinuria.
Description of the intervention
The definitive treatment of hypertensive disorders related to preg-
nancy is planned early delivery. The alternative is to manage the
pregnancy expectantly with close maternal and fetal monitoring.
The generic Cochrane protocols on interventions for preventing
(Meher 2005) and treating (Duley 2009) pre-eclampsia and its
consequences cite various Cochrane Reviews covering this subject.
The World Health Organization (WHO) guidelines on preven-
tion and treatment of pre-eclampsia and eclampsia provide a sum-
mary of available evidence on various interventions (WHO2011).
There are currently no data from randomised controlled trials on
interventions to monitor women with hypertensive disorders of
pregnancy.
The general approach on management involves frequent blood
pressure measurement, frequent assessment ofmaternal symptoms
(headache, blurred vision, epigastric or abdominal pain, vaginal
bleeding, decrease in fetal movements), urine analysis for protein
with urine dipstick or ratio of protein to creatinine, and blood
tests to assess renal and liver function, platelets and haemoglo-
bin depending on the severity of the condition. For pre-eclampsia
bloods are taken at least twice weekly if the maternal condition is
stable or more frequently if there is any suspicion of clinical dete-
rioration. For chronic hypertension and gestational hypertension,
bloods are not routinely taken. Fetal monitoring is done by assess-
ing fetal movements felt by themother, fetal heart rate monitoring
and fetal ultrasound (amniotic fluid measurement, fetal growth,
and Doppler velocimetry in the umbilical artery, middle cerebral
artery and ductus venosus) (Norwitz 2013).
Indications for delivery of women being managed expectantly
would include deterioration of blood pressure control despite an-
tihypertensive treatment, new onset maternal symptoms which
include severe headache, blurred vision, epigastric or abdominal
pain, vaginal bleeding and a decrease in fetal movements, deteri-
oration in blood tests and a change in fetal condition.
Bed rest (Meher 2005), dietary salt restriction (Meher 2005), vi-
tamin D supplementation (De Regil 2011), vitamin C and E sup-
plementation, and thiazide diuretics are not recommended for
prevention of pre-eclampsia (WHO 2011). Calcium supplemen-
tation is recommended in areas with low dietary calcium intake
(Hofmeyr 2014). Low-dose aspirin, started before 16 weeks, is
recommended for the prevention of pre-eclampsia in women who
have risk factors for pre-eclampsia (Bujold 2014). Based on expert
opinion, severe hypertension during pregnancy should be treated
with antihypertensive drugs and the choice of the drug is left to
the clinician managing the woman (WHO 2011).
The timing of delivery is based on the severity of the maternal
condition, gestational age and fetal condition. The indications for
planned early delivery (or contraindications for expectant man-
agement) include: instability of maternal condition; persistent se-
vere hypertension unresponsive tomedical therapy; persistent pro-
gressive or severe headache; visual disturbances; eclampsia; cere-
brovascular events; posterior reversible encephalopathy syndrome
(PRES); epigastric or abdominal pain; left ventricular failure; pul-
monary oedema; severe renal impairment with a creatinine level
greater than or equal to 125 µmol/l; the need for dialysis or re-
nal failure; abruptio placenta; non-reassuring fetal testing (non-
reassuring fetal heart rate tracing, estimated fetal weight less than
fifth centile, oligohydramnios, persistent absent or reversed end-
diastolic flow in umbilical artery Doppler); fetal demise; labora-
tory abnormalities (liver transaminases greater than or equal to
500 IU/L, progressive decrease in platelet count to less than 100 ×
109/L, coagulopathy with an INR greater than 2 in the absence of
an alternative cause); preterm labour; preterm premature rupture
of membranes; HELLP syndrome (Norwitz 2013).
The potential implications for the mother and fetus of expectant
management are weighed against the possible complications of an
earlier delivery.
Traditionally, the management of hypertensive disorders in preg-
nancy at or near term (from 34 weeks onwards) has been a planned
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early delivery by induction of labour or caesarean section. Cur-
rently, there is a tendency in high-income countries to continue
with expectantmanagement in the absence of severe pre-eclampsia
past 34 0/7 gestational weeks. Canadian guidelines recommend
planned early delivery after 37 0/7 weeks in case of pre-eclampsia
and expectant management before 34 0/7 weeks. In case of non-
severe pre-eclampsia there is insufficient evidence to recommend
planned early delivery between 34 0/7 to 36 6/7 weeks (Magee
2008).
Based on a recent literature review by Spong 2011, planned early
delivery is recommended:
• at 38 to 39 weeks for women with chronic hypertension on
no medications;
• at 37 to 39 weeks for women with chronic hypertension
controlled on medications;
• at 36 to 37 weeks for women with chronic hypertension
difficult to control;
• at 37 to 38 weeks for women with gestational hypertension;
• at diagnosis for women with severe pre-eclampsia (at or
after 34 weeks);
• at 37 weeks for women with mild pre-eclampsia.
How the intervention might work
Planned early delivery by induction of labour or indicated cae-
sarean section is thought to have the following benefits:
• prevention of severe maternal complications in women with
hypertensive disorders in pregnancy;
• prevention of poor fetal outcomes and stillbirth.
Potential risks of planned early delivery by induction of labour are:
• increased risk of complications associated with induction of
labour such as uterine hyperstimulation and fetal distress;
Potential risks of planned early delivery by induction of labour or
caesarean section are:
• concerns related to prematurity. Although the adverse
outcomes due to prematurity are uncommon after 34 0/7 weeks
of gestation, several recent reports have highlighted increased
rates of neonatal morbidity related to respiratory distress
syndrome, need for ventilation and neonatal intensive care
admission when elective caesarean sections were performed
before 39 0/7 weeks of gestation (Maslow 2000; Tita 2009;
Wilmink 2010). Infants born between 37 0/7 and 38 6/7 weeks
have greater neonatal morbidity during the first year of life in
comparison with infants born between 39 0/7 and 41 0/7 weeks
(Dietz 2012). Near-term infants have significantly more health
problems and increased healthcare costs compared with full-term
infants in the first year of life and later on (Boyle 2012; Wang
2004).
The intervention being investigated is timing of delivery. Prolong-
ing gestation may be better for the fetus but it may increase the
risks of complications for the mother.
Why it is important to do this review
There are benefits and risks associated with both policies (planned
early delivery and expectant management) in women with hyper-
tensive disorders of pregnancy. It is therefore important to estab-
lish the safest option associated with more favourable maternal
and neonatal outcomes in such cases.
Management of severe pre-eclampsia before term is dealt with in
another Cochrane Review comparing interventionist and expec-
tant care (Churchill 2013).
O B J E C T I V E S
To assess the benefits and risks of a policy of planned early delivery
versus a policy of expectant management in pregnant women with
hypertensive disorders, at or near term (from 34 weeks onwards).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included adequately randomised controlled trials comparing
planned early delivery (induction of labour or caesarean section)
with expectant management of women with hypertensive disor-
ders from 34 weeks’ gestation to term. We would have included
cluster-randomised trials butwe foundnone. Studies using a quasi-
randomised design are not eligible for inclusion in this review.
Similarly, studies using a cross-over design are not eligible for in-
clusion, because they are not a suitable study design for investi-
gating hypertensive disorders in pregnancy.
Types of participants
Womenwith hypertensive disorders at 34weeks 0 days of gestation
or longer.
Types of interventions
Comparison of a policy of planned early delivery (by induction of
labour or by caesarean section) with a policy of delayed delivery
(expectant management).
Types of outcome measures
Primary outcomes
8Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1. Composite maternal outcome, including maternal
mortality (death during pregnancy or up to 42 days after
delivery) and severe morbidity (eclampsia; cerebral vascular
event; pulmonary oedema as defined by trial authors; severe renal
impairment, defined as a creatinine level greater than 125 µmol/
l or a need for dialysis or urine output less than 0.5 mL/kg/hour
for four hours unresponsive to hydration with two intravenous
boluses, or as defined by trial authors; liver haematoma or
rupture; liver failure, defined as the rapid impairment of
synthetic function and development of encephalopathy or as
defined by trial authors; haemolysis elevated liver enzymes and
low platelets (HELLP) syndrome; disseminated intravascular
coagulation (DIC); thromboembolic disease; and abruptio
placentae, defined as a retroplacental clot of more than 15% of
the maternal surface or as defined by trial authors).
2. Composite perinatal outcome, including fetal or neonatal
death (within six weeks after the expected due date or as defined
by trial authors); grade III or IV intraventricular or intracerebral
haemorrhage; necrotising enterocolitis (NEC); acute respiratory
distress syndrome (ARDS) or grade III/IV hyaline membrane
disease; small-for-gestational age (growth below the 10th centile
or as defined by trial authors); and neonatal seizures.
Secondary outcomes
Maternal
1. Maternal mortality as described above
2. Eclampsia
3. Cerebrovascular event
4. Pulmonary oedema as defined above
5. Severe renal impairment as defined above
6. Liver haematoma or rupture*
7. Liver failure as defined above
8. HELLP syndrome
9. DIC
10. Thromboembolic disease
11. Abruptio placentae
12. Antepartum haemorrhage
13. Postpartum haemorrhage (blood loss of more than 500 mL
or more within 24 hours of delivery)
14. Severe hypertension (systolic blood pressure greater than or
equal to 160 mmHg or a diastolic blood pressure greater than
110 mmHg)
15. Caesarean section
16. Assisted delivery (ventouse/forceps)
17. Maternal morbidity of caesarean section (wound infection,
wound dehiscence, endometritis, postpartum haemorrhage
(blood loss greater than 500 mL), urinary or bowel problems,
venous thrombosis)
18. Maternal morbidity related to induction of labour (uterine
hyperstimulation, uterine rupture, hyponatraemia, hypotension,
chorioamnionitis, cord prolapse, failed induction)
19. Admission to a high care or intensive care unit*
20. Women’s experiences and views on the interventions:
pregnancy and childbirth experience, physical and psychological
trauma, mother-infant interaction and attachment
Fetal and neonatal
1. Fetal death
2. Neonatal death as defined above
3. Grade III or IV intraventricular or intracerebral
haemorrhage
4. NEC
5. ARDS or grade III/IV hyaline membrane disease
6. Small-for-gestational age as defined by trial authors
7. Neonatal seizures
8. Apgar score less than seven at five minutes
9. Cord blood pH less than 7.1 or as defined by trial authors
10. Surfactant use*
11. Neonatal intensive care unit or high care unit admission*
12. Intubation and mechanical ventilation or continuous
positive airway pressure support
13. Early neonatal sepsis*
Use of health-service resources
1. Duration of hospital stay after delivery for mother
2. Duration of hospital stay after delivery for baby
Economic outcomes
1. Costs to health service resources: short-term and long-term
for both mother and baby
2. Costs to the woman, her family, and society
* denotes that outcome was not specified in this review’s protocol
and was added at the review stage.
Search methods for identification of studies
The followingMethods sectionof this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (1 January 2016).
The Register is a database containing over 22,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter including the detailed search strategies for CENTRAL, MED-
LINE, Embase and CINAHL; the list of handsearched journals
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and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about the Cochrane Pregnancy and Childbirth
in the Cochrane Library and select the ‘Specialized Register ’ sec-
tion from the options on the left side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in a more specific search set which has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies; Ongoing studies).
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
The followingMethods sectionof this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors independently assessed all the potential studies
we identified as a result of the search strategy. We resolved any
disagreement through discussion and did not need to consult a
third person.
We included one study published in abstract only, as it was assessed
as eligible (Majeed 2014).
Data extraction and management
Wedesigned a form to extract data. For eligible studies, two review
authors extracted the data using the agreed form. We resolved
discrepancies through discussion and did not need to consult a
third person. We entered data into Review Manager 5 software
(RevMan 2014) and checked them for accuracy.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risks of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We resolved
any disagreement by discussion and did not need to involve a third
assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively-numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes; alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received.We considered that studies are
at low risk of bias if theywere blinded, or we judged that the lack of
blinding would be unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
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(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we re-included missing data in the analyses
which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups and are unlikely to
influence the outcome; missing data have been imputed using
appropriate methods);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (where not all the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
have about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book (Higgins 2011). With reference to (1) to (6) above, we as-
sessed the likely magnitude and direction of the bias and whether
we considered it was likely to impact on the findings. We explored
the impact of the level of bias through undertaking sensitivity
analyses - see Sensitivity analysis.
Assessment of the quality of the evidence using the
GRADE approach
We assessed the quality of the evidence using the GRADE ap-
proach, as outlined in the GRADE Handbook in order to assess
the quality of the body of evidence relating to the following out-
comes for the main comparison (Planned early delivery versus ex-
pectant management (all women)):
1. Composite maternal outcome including maternal mortality
(death during pregnancy or up to 42 days after delivery) and
severe morbidity (eclampsia; cerebral vascular event; pulmonary
oedema, as defined by trial authors; severe renal impairment,
defined as a creatinine level greater than 125 µmol/l or a need
for dialysis or urine output less than 0.5 mL/kg/hour for four
hours unresponsive to hydration with two intravenous boluses,
or as defined by trial authors; liver haematoma or rupture; liver
failure, defined as the rapid impairment of synthetic function
and development of encephalopathy or as defined by trial
authors; haemolysis elevated liver enzymes and low platelets
(HELLP) syndrome; disseminated intravascular coagulation
(DIC); thromboembolic disease; and abruptio placentae, defined
as a retroplacental clot of more than 15% of the maternal surface
or as defined by trial authors).
2. Composite perinatal outcome including fetal or neonatal
death (within six weeks after the expected due date or as defined
by trial authors); grade III or IV intraventricular or intracerebral
haemorrhage; necrotizing enterocolitis (NEC); acute respiratory
distress syndrome (ARDS) or grade III/IV hyaline membrane
disease; small-for-gestational age (growth below the 10th centile
or as defined by trial authors); and neonatal seizures.
3. Caesarean section.
4. Duration of hospital stay for mother after delivery.
5. Duration of hospital stay for fetus after delivery.
GRADEpro Guideline Development Tool was used to import
data from Review Manager 5 (RevMan 2014) in order to create
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’Summary of findings’ tables. We produced a summary of the
intervention effect and a measure of quality for each of the above
outcomes, using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence can be
downgraded from ’high quality’ by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency,
imprecision of effect estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we present results as a summary risk ratio
(RR) with a 95% confidence interval (CI).
Continuous data
For continuous data, we used themean difference if outcomeswere
measured in the sameway between trials.We used the standardised
mean difference to combine trials that measure the same outcome,
but using different methods.
Unit of analysis issues
Cluster-randomised trials
We did not identify any cluster-randomised trials in the analy-
ses. If we had, we would have followed Chapter 16.3 of Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011)
to perform analysis of cluster-randomised trials. We would have
calculated the intra-cluster correlation coefficient (ICC) and de-
sign effect. We would have multiplied the standard error of the
effect estimate (from analysis ignoring clustering) by the square
root of the design effect. We would have performed meta-analysis
using the inflate variances and the generic inverse-variancemethod
(Chapter 16.3.6 Higgins 2011).
Cross-over trials
Cross-over trials are inappropriate for this intervention.
Multi-armed trials
We did not identify any multi-armed trials. If we had, we would
have combined all relevant experimental intervention groups of
the study into a single group and all relevant control intervention
groups into a single control group when we analysed the data.
If we had considered one of the arms irrelevant, we would have
excluded it from analysis.
Dealing with missing data
For included studies, we noted levels of attrition. We did not
need to explore the impact of including studies with high levels of
missing data in the overall assessment of treatment effect by using
sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on an
intention-to-treat basis, i.e. we attempted to include all partici-
pants randomised to each group in the analyses, and analysed all
participants in the group to which they were allocated, regardless
of whether or not they received the allocated intervention. The
denominator for each outcome in each trial was the number ran-
domised minus any participants whose outcomes are known to be
missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T2, I2 and Chi2 statistics. We regarded heterogeneity as sub-
stantial if an I2 was greater than 30% and either a T2 was greater
than zero, or there was a low P value (less than 0.10) in the Chi2
test for heterogeneity.
Assessment of reporting biases
There were fewer than 10 studies in the meta-analysis. In future
updates of this review, if there are 10 or more studies in a meta-
analysis, we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager 5
software (RevMan 2014). We used a fixed-effect meta-analysis for
combining data where it is reasonable to assume that studies are
estimating the same underlying treatment effect, i.e. where trials
are examining the same intervention, and the trials’ populations
and methods are judged sufficiently similar. If there was clinical
heterogeneity sufficient to expect that the underlying treatment
effects differ between trials, or if we detected substantial statistical
heterogeneity, we would have used a random-effects meta-analy-
sis to produce an overall summary, if an average treatment effect
across trials was considered clinically meaningful. We would have
treated the random-effects summary as the average range of pos-
sible treatment effects and we would have discussed the clinical
implications of treatment effects differing between trials. If the
average treatment effect was not clinically meaningful, we would
not combine trials.
Where we use random-effects analyses, we present the results as
the average treatment effect with its 95% confidence interval, and
the estimates of T2 and I2.
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Subgroup analysis and investigation of heterogeneity
If we had identified substantial heterogeneity, we would have in-
vestigated it using subgroup analyses and sensitivity analyses. We
would have considered whether an overall summary is meaning-
ful, and if it was, we would have used random-effects analysis to
produce it.
We carried out the following subgroup analyses:
1. Women at 34 weeks 0 days to 36 weeks 6 days of gestation
versus 37 weeks 0 days to 38 weeks 6 days versus more then 39
weeks of gestation.
2. Each gestational week.
3. Women with pre-eclampsia only versus women with
gestational hypertension (mild, not severe) only or pre-existing
hypertension only.
We used the following primary outcomes in subgroup analysis.
1. composite maternal
2. composite perinatal outcome
Broekhuijsen 2015 has not yet published the composite outcomes
by gestational age, so we also carried out subgroup analysis using
the outcome respiratory distress syndrome.
We assessed subgroup differences by interaction tests available
within RevMan (RevMan 2014). We reported the results of sub-
group analyses quoting the Chi2 statistic and P value, and the in-
teraction test I2 value.
Sensitivity analysis
We did not need to perform sensitivity analysis for primary out-
comes, as we did not identify substantial heterogeneity in the in-
cluded studies.
It was not indicated to perform sensitivity analyses for aspects of
the review that might affect the results; for example, where there
is a risk of bias associated with the quality of some of the included
trials; or to explore the effects of fixed-effect or random-effects
analyses for outcomes with statistical heterogeneity; and to explore
the effects of any assumptions made, such as the value of the ICC
used for cluster-randomised trials.
Wewould have used the followingoutcomes in sensitivity analyses.
1. Composite maternal outcome.
2. Composite perinatal outcome.
R E S U L T S
Description of studies
Results of the search
The search of Cochrane Pregnancy and Childbirth’s Register re-
trieved 24 trial reports, and we found one additional report
through other sources. These reports corresponded to eight stud-
ies. Five of these studies (22 reports) fulfilled the eligibility crite-
ria for the review (Broekhuijsen 2015; Hamed 2014; Koopmans
2009; Majeed 2014; Owens 2014). Two studies (two reports)
were excluded (Ramrakhyani 2001; Tukur 2007), and one study
(Shennan 2013) is ongoing and will be eligible for inclusion when
it is complete (See: Figure 1).
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Figure 1. Study flow diagram.
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Included studies
We included five studies (involving 1819 women) in this review (
Broekhuijsen 2015;Hamed2014;Koopmans 2009;Majeed2014;
Owens 2014). See Characteristics of included studies.
Design
All five of the included studies were two-arm randomised con-
trolled trials, comparing planned early delivery with expectant
management for hypertensive disorders from 34 weeks to term.
Sample sizes
Two of the studies were large multicentre trials (Broekhuijsen
2015; Koopmans 2009), which recruited 704 and 756 women
respectively. Hamed 2014 recruited 76 women at two hospitals.
Two studies took place in a single centre, recruiting 100 women
(Majeed 2014), and 183 women (Owens 2014).
Setting
The two largemulticentre trialswere conducted in theNetherlands
(Broekhuijsen 2015; Koopmans 2009). Three smaller studies were
carried out in India (Majeed 2014),USA (Owens2014), andSaudi
Arabia and Egypt (Hamed 2014).
Participants
The gestational age ranges of women eligible for the studies were
36 to 41 weeks (Koopmans 2009), 36 to 40 weeks (Majeed 2014),
34 to 37 weeks (Broekhuijsen 2015; Owens 2014), and 24 to 36
weeks (Hamed 2014).
The type of hypertensive disorder included varied between stud-
ies: Koopmans 2009 andMajeed 2014 included pregnant women
with gestational hypertension or mild pre-eclampsia, Owens 2014
includedwomenwithmild pre-eclampsia only, Broekhuijsen 2015
recruited women with gestational hypertension, mild pre-eclamp-
sia or deteriorating chronic hypertension. Hamed 2014 was the
only trial to concentrate on women with chronic hypertension
(mild to moderate, without proteinuria, diagnosed before 20
weeks’ gestation or if the woman was known to be hypertensive
before pregnancy). Women were not eligible to participate in this
study if they had gestational hypertension or new onset of pre-
eclampsia where previously normotensive, in contrast to Owens
2014 and Koopmans 2009 where only women who had newly
identified hypertension could participate.
Of the studies that included women with pre-eclampsia, they all
excluded women with severe pre-eclampsia. Broekhuijsen 2015
and Koopmans 2009 excluded women who had a diastolic blood
pressure ≥ 110 mmHg despite medication, a systolic blood pres-
sure ≥ 170 mmHg despite medication, proteinuria ≥ 5 g per
24 hours, eclampsia, HELLP syndrome, pulmonary oedema or
cyanosis, oliguria less than 500 mL in 24 hours, renal disease,
heart disease, and severe pre-eclamptic complaints such as frontal
headache or ruptured membranes. Majeed 2014 excluded women
if the systolic blood pressure was above 160 mmHg, if the diastolic
blood pressure was above 110 mmHg or if there was more than
5 g proteinuria per 24-hour collection. Owens 2014 excluded all
that did not have mild pre-eclampsia.
Studies had different inclusion and exclusion criteria for partici-
pants, some concerning factors that may be related to, or result
from, hypertensive disorders. For example, multiple pregnancies,
pre-existing diabetes, and suspected intrauterine growth restric-
tion. Broekhuijsen 2015 had the most inclusive eligibility crite-
ria, potentially meaning that the population of women recruited
to this study were more representative of women with hyperten-
sive disorders. Multiple pregnancies were excluded from Hamed
2014, Koopmans 2009 and Owens 2014, but not excluded in
Broekhuijsen 2015. In this study, 44 participants out of 703 had
multifetal gestations (18 out of 352 randomised to planned early
delivery, 26 out of 351 randomised to expectant monitoring), and
the infant outcomes were deemed present if at least one neonate
was affected. Women with diabetes mellitus were excluded from
Hamed2014,Koopmans 2009 andOwens 2014, but not excluded
from Broekhuijsen 2015. Women who had a previous caesarean
section were excluded from Hamed 2014 and Koopmans 2009,
but not excluded from Broekhuijsen 2015. Babies with suspected
intrauterine growth restriction or small-for-gestational age were
excluded from Koopmans 2009 and Owens 2014, but were not
excluded from Broekhuijsen 2015. Women taking antihyperten-
sive medication were excluded from Owens 2014, excluded if the
medication was intravenous in Koopmans 2009, and eligible to
participate in Broekhuijsen 2015. Majeed 2014 did not describe
the exclusion criteria or detailed inclusion criteria.
Interventions
Two studies compared an intervention group who had labour in-
duced before term: at 34 to 36 weeks’ gestation (Broekhuijsen
2015) and at 34 to 37 weeks (Owens 2014), with a comparison
group who were monitored until 37 weeks’ gestation when induc-
tion began, if labour had not started spontaneously. Three studies
compared induction of labour at term or closer to term: at 37 com-
pleted weeks (Hamed 2014) and at 36 to 41 weeks (Koopmans
2009;Majeed 2014) in the intervention group, with a comparison
group who were monitored until 41 weeks when induction began,
if labour had not started spontaneously.
In the intervention groups, infants were delivered by induction of
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labour, or by caesarean section if necessary. Three studies placed a
time limit on this intervention, within 12 hours (Owens 2014) or
24 hours (Broekhuijsen 2015; Koopmans 2009) of randomisation.
Labour was induced and augmented with amniotomy and oxy-
tocin (Broekhuijsen 2015;Hamed 2014; Koopmans 2009). If nec-
essary cervical ripening was stimulated with intracervical or intrav-
aginal prostaglandins or a balloon catheter (Broekhuijsen 2015;
Koopmans 2009) or with vaginal misoprostol (Hamed 2014).
Women in the expectant management group were monitored
as outpatients (Hamed 2014), inpatients (Owens 2014), or in
an inpatient or outpatient setting depending on their condition
(Broekhuijsen 2015; Koopmans 2009). Monitoring consisted of
measuring maternal blood pressure and screening of urine for pro-
tein (Broekhuijsen 2015; Hamed 2014; Koopmans 2009), look-
ing for signs of disease progression with severe features of pre-
eclampsia (Owens 2014), mother’s assessment of fetal movements
and electronic fetal heart rate monitoring (Broekhuijsen 2015;
Koopmans 2009), non-stress testing (Owens 2014), and ultra-
sound examination (Koopmans 2009). Majeed 2014 did not pro-
vide information on the nature of the monitoring.
Outcomes
The two largest trials (Broekhuijsen 2015; Koopmans 2009) re-
ported the composite outcome for maternal mortality and mor-
bidity, and a composite outcome for perinatal mortality and mor-
bidity, defined as the primary outcomes in this review. In addition,
these trials reported maternal and infant mortality and morbidity
outcomes individually. Maternal mortality was not reported by
the other three trials (Hamed 2014; Majeed 2014; Owens 2014),
and two trials did not report perinatal mortality (Majeed 2014;
Owens 2014).
All studies reported on disease progression, for example, the
development of severe hypertension, defined in a variety of
ways (Hamed 2014; Koopmans 2009; Owens 2014), eclamp-
sia (Broekhuijsen 2015; Koopmans 2009), HELLP syndrome
(Broekhuijsen 2015; Koopmans 2009; Owens 2014), and acute
renal failure (Majeed 2014). Adverse infant outcomes were re-
ported for all trials except Majeed 2014. These include possible
consequences of early delivery for the infants, such as respiratory
distress syndrome (Broekhuijsen 2015; Koopmans 2009; Owens
2014), and neonatal intensive care unit admission (Broekhuijsen
2015; Hamed 2014; Koopmans 2009; Owens 2014).
Majeed 2014 was presented as a poster abstract, and the data were
therefore limited. We contacted the authors for additional infor-
mation, but have not received a reply. The most comprehensive
reporting of outcomes was by Broekhuijsen 2015 and Koopmans
2009, with both trials presented across multiple published reports.
Funding sources
Two studies (Broekhuijsen 2015;Koopmans 2009)were fundedby
ZonMw, the Netherlands Organisation for Health Research and
Development. Hamed 2014 and Owens 2014 were both funded
through their affiliated universities: Qassim University and the
University of Mississippi Medical Centre, respectively. As Majeed
2014 was presented as a poster abstract, with limited information
given, it is not clear who provided funding for this study.
Declarations of interest
None of the study authors declared any conflicts of interest. This
was not mentioned in Majeed 2014.
Excluded studies
We excluded two studies (two reports); one because it was not a
randomised controlled trial, with group allocation based on ges-
tational age at presentation (Ramrakhyani 2001), and the other
compared two methods of planned early delivery: caesarean sec-
tion and induction with vaginal misoprostol (Tukur 2007). See
Characteristics of excluded studies.
Ongoing studies
We found one ongoing study (Shennan 2013). This trial com-
pares planned early delivery with monitoring until induction at
37 weeks’ gestation, for pregnant women with pre-eclampsia be-
tween 34 and 37 weeks of gestation. According to the protocol,
recruitment started in April 2014, and it was anticipated that it
will take approximately three years to recruit 900 women. See
Characteristics of ongoing studies.
Risk of bias in included studies
Assessment of the methodological quality of the included studies
was based on risk of bias in relation to selection bias (method
of randomisation and allocation concealment), performance bias,
detection bias, attrition bias (loss of participants from the analyses)
and reporting bias. A summary of ’Risk of bias’ assessments for
each study, and for included trials overall, are set out in Figure 2
and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Generation of the randomisation sequence
Three studies reported using a computerised or web-based ran-
dom-number generator to generate the randomisation sequence,
which we judged were at low risk of bias (Broekhuijsen 2015;
Hamed 2014; Koopmans 2009). We judged the remaining two
studies to be at unclear risk of bias: Owens 2014 described using
stratified and random permuted blocks of two but did not describe
how the randomisation sequence was generated, andMajeed 2014
did not mention the method for determining the randomisation
sequence.
Allocation concealment
In two of the studies, the method for concealing group allocation
at the point of randomisation was not clear (Hamed 2014;Majeed
2014). Three studies were at low risk of bias: Owens 2014 con-
cealed allocation in sealed envelopes, and the web-based central
allocation of Broekhuijsen 2015 and Koopmans 2009 concealed
their allocation.
Blinding
The blinding of women and health professionals was not possi-
ble for this intervention. This may have had an effect on other
treatment decisions. All included studies have consequently been
assessed as high risk of bias due to lack of blinding.
Incomplete outcome data
We considered the risk of bias to be low in Broekhuijsen 2015,
Hamed 2014 and Koopmans 2009, as all women were accounted
for and there was little or no attrition. The number of women
allocated to each group was not reported by Majeed 2014, so we
judged the risk of bias to be unclear as we cannot assess whether
data for all women are reported. There was some attrition from
Owens 2014, and the data were not presented as intention-to-
treat, so we considered that the risk of bias is also unclear for this
trial.
Selective reporting
Protocols were available for Broekhuijsen 2015, Koopmans 2009
and Owens 2014. All prespecified outcomes were reported for
these trials, so we judged these to be at a low risk of reporting
bias. Reporting appeared to be good in Hamed 2014, however no
protocol was available to assess whether all prespecified outcomes
were reported, so risk of bias was unclear. Majeed 2014 was as-
sessed from a poster-presentation abstract, which only reported
significant findings, and was therefore at high risk of bias.
Other potential sources of bias
Owens 2014 was stopped early due to a change in hospital policy,
at 74% of the enrolment target, leaving the study underpowered to
demonstrate statistically significant differences, with unclear im-
plications for the risk of other bias. The baseline characteristics of
women assigned to the planned delivery and expectant monitor-
ing groups appear to be similar in all studies, so there is low risk
of other potential sources of bias for Broekhuijsen 2015, Hamed
2014, Koopmans 2009, and Majeed 2014.
Effects of interventions
See: Summary of findings for the main comparison Planned
early delivery versus expectant management for hypertensive
disorders from 34 weeks’ gestation to term
Planned early delivery versus expectant management
See Summary of findings for the main comparison. We included
five studies, involving 1819 women.
Primary outcomes
Two studies reported thecomposite maternal outcome, includ-
ing maternal mortality and severe morbidity (Broekhuijsen
2015; Koopmans 2009). There was a lower risk of these severe
adverse outcomes for women randomised to planned early deliv-
ery (risk ratio (RR) 0.69, 95% confidence interval (CI) 0.57 to
0.83, two studies, 1459 women, evidence graded high, Analysis
1.1). There were no clear differences between groups based on our
subgroup analysis by gestational age, gestational week or condition
(see Analysis 2.1; Analysis 3.1; Analysis 4.1).
The same two studies also reported the composite perinatal out-
come (including fetal or neonatal death and serious morbid-
ity). There was not enough information to draw any conclusions
about the effects on neonatal mortality and serious morbidity.
Meta-analysis was not possible, due to substantial heterogeneity (I
2 = 87%, Tau2 = 0.98) for this outcome between these two studies
(1459 infants, Analysis 1.2). It is worth noting that Broekhuijsen
2015 found that infants in the planned early delivery group had
a higher risk of respiratory distress syndrome than those in the
expectant management group (RR 3.32, 95% CI 1.35 to 8.18,
703 infants, Analysis 2.2) with planned early delivery taking place
at 34 to 37 weeks’ gestation. However Koopmans 2009 showed
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no evidence of differences in composite infant mortality and mor-
bidity (RR 0.77, 95% CI 0.46 to 1.28, 756 infants, Analysis 2.3)
with planned early delivery taking place later, at 36 to 41 weeks’
gestation. There were no clear differences between groups based on
our subgroup analysis by gestational age or gestational week (see
Analysis 2.3; Analysis 3.2; Analysis 3.3). However Broekhuijsen
2015 have not yet published the composite outcomes by gesta-
tional age, so any possible adverse effects on infants born at the
earliest gestations have not yet been explored.
Secondary outcomes
Maternal
There were no incidences ofmaternal mortality in the two stud-
ies that reported it (1457 women, Analysis 1.3). We found no
clear differences between delivery and expectant management for
the number of women experiencing eclampsia (RR 0.20, 95%
CI 0.01 to 4.14, 1459 women, two studies, Analysis 1.4). There
were no events reported forpulmonary oedema (703women, one
study, Analysis 1.5). Women who were assigned planned early de-
livery had a lower risk of severe renal impairment (RR 0.36, 95%
CI0.14 to 0.92, 100women, one study, Analysis 1.6), andHELLP
syndrome (RR 0.40, 95% CI 0.17 to 0.93, 1628 women, three
studies, Analysis 1.7) than women assigned to expectant manage-
ment. We found no clear differences between planned early de-
livery and expectant management for the number of women ex-
periencing thromboembolic disease (RR 1.67, 95% CI 0.22 to
12.58, 1459 women, two studies, Analysis 1.8), abruptio placen-
tae (RR 0.64, 95% CI 0.17 to 2.34, 1535 women, three studies,
Analysis 1.9), or postpartum haemorrhage (RR 0.88, 95% CI
0.57 to 1.35, 741 women, one study, Analysis 1.10).
There was high heterogeneity between studies for women devel-
oping severe hypertension (I2 = 79%, Tau2 = 0.83). There was
not enough information to draw any conclusions about the ef-
fects on severe hypertension (995 women, three studies, Analysis
1.11). Two studies (919 women) reporting this outcome found
that planned early delivery was less likely to result in the progres-
sion to severe hypertension, while one study (74 women) found no
difference. The study that found no difference had recruited preg-
nant women with chronic hypertension (Hamed 2014), while the
women in the other two studies had mild pre-eclampsia (Owens
2014), gestational hypertension ormild pre-eclampsia (Koopmans
2009).
We found no clear differences between planned early delivery and
expectant management for caesarean section (RR 0.91, 95% CI
0.78 to 1.07, 1728 women, four studies, evidence graded moderate,
Analysis 1.12), assisted delivery (ventouse/forceps) (RR 0.93,
95% CI 0.70 to 1.24, 1459 women, two studies, Analysis 1.13),
or endometritis (maternal morbidity of caesarean section) (RR
0.75, 95% CI 0.17 to 3.35, 756 women, one study, Analysis
1.14). There were no events reported for uterine rupture (ma-
ternal morbidity related to induction of labour) (756 women,
one study, Analysis 1.15). We found no clear differences between
planned early delivery and expectant management for maternal
admission to a high care or intensive care unit (RR 0.41, 95%
CI 0.16 to 1.07, 708 women, one study, Analysis 1.16).
Women’s experiences and views on the interventions were not
reported in any of the included studies. However, Koopmans
2009 assessed women’s health-related quality of life after planned
early delivery or expectant management. They administered the
Short-Form (SF-36), European Quality of Life (EuroQoL 6D3L),
Hospital Anxiety and Depression Scale (HADS), and Symptom
Checklist (SCL-90). Measurements were at baseline, six weeks
postpartum and six months postpartum. They found no clear dif-
ference in these measures of health-related quality of life. (The
numeric results are not presented in this review, because the out-
comes do not correspond to those prespecified in the protocol.
However, as these are important issues we have included this nar-
rative summary of the results).
Several of the outcomes for this review were not reported by trial
authors: cerebrovascular event, liver haematoma or rupture,
liver failure as defined above, dissemination intravascular co-
agulation, and antepartum haemorrhage.
Fetal and neonatal
One study reportedfetal death, with no events (756 infants,
Analysis 1.17). There were very few events, and therefore not
enough information to see if there was a difference in neonatal
death (RR 2.00, 95% CI 0.19 to 21.14, 1535 infants, three stud-
ies, Analysis 1.18) and grade III or IV intraventricular or in-
tracerebral haemorrhage (RR 6.92, 95% CI 0.36 to 133.41, 674
infants, one study, Analysis 1.19). We found no clear difference
in the numbers of infants with nectrotising enterocolitis (RR
0.98, 95% CI 0.14 to 6.89, 1338 infants, two studies, Analysis
1.20). Babies allocated to planned early delivery had a higher risk
of acute respiratory distress syndrome or grade III/IV hyaline
membrane disease (RR 2.24, 95% CI 1.20 to 4.18, 1511 infants,
three studies, Analysis 1.21). Therewas no clear difference between
groups assigned to planned early delivery or expectant monitor-
ing for small-for-gestational age as defined by trial authors (RR
1.58, 95% CI 0.89 to 2.79, 1001 infants, three studies, Analysis
1.22), neonatal seizures (RR 3.97, 95% CI 0.45 to 35.30, 699
infants, one study, Analysis 1.23), Apgar score less than seven
at five minutes (RR 1.11, 95% CI 0.60 to 2.05, 1454 infants,
two studies, Analysis 1.24), and cord blood pH less than 7.1 or
as defined by trial authors (RR 0.58, 95% CI 0.31 to 1.09, 1145
infants, two studies, Analysis 1.25). In the one study that reported
surfactant use, no infants required it (639 infants, Analysis 1.26).
Babies in the group allocated to planned early delivery were more
likely to be admitted to neonatal intensive care unit or high
care unit than those allocated to expectantmanagement (RR1.65,
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95% CI 1.13 to 2.40, 1585 infants, four studies, Analysis 1.27).
Intubation and mechanical ventilation or continuous positive
airway pressure supportwas not reported in any of the included
studies. There was a substantial difference in the incidence of early
neonatal sepsis between the two studies that reported it, so results
have not been pooled (1455 infants, two studies, Analysis 1.28).
Use of health-service resources
There was no clear difference in the duration of hospital stay
after delivery for mother (mean difference (MD) -0.16 days,
95% CI -0.46 to 0.15; 925 women, two studies, evidence graded
moderate, Analysis 1.29), and no clear difference in the duration
of hospital stay after delivery for baby (MD -0.20 days, 95%
CI -0.57 to 0.17, 756 infants, one study, evidence graded moderate,
Analysis 1.30).
Economic outcomes
The costs to health service resources: short-termand long-term
for both mother and baby and costs to the woman, her family,
and society were not reported in the included studies.
D I S C U S S I O N
Summary of main results
We included five studies involving 1819 women, comparing
planned early delivery versus expectant management for hyper-
tensive disorders from 34 weeks to term.
Fewer women who had hypertensive disorders of pregnancy ex-
perienced severe adverse outcomes (composite maternal mortality
and severe morbidity) when they were allocated to planned early
delivery. Planned early delivery was also associated with lower lev-
els of HELLP syndrome and severe renal impairment. There was
no clear difference in any of the other maternal outcomes reported
by the included studies.
There was not enough information to draw any conclusions about
the effects on neonatal mortality and severe morbidity, as there
were limited data assessing all hypertensive disorders as one group.
Planned early delivery was associated with higher levels of res-
piratory distress syndrome, and NICU admission. There was no
clear difference for other infant outcomes reported by the included
studies.
No difference was shown between planned early delivery and ex-
pectant management in the proportion of women needing a cae-
sarean section, and in the duration of hospital stay after delivery
for mother or baby.
(See Summary of findings for the main comparison.)
Overall completeness and applicability of
evidence
The studies included in this review addressed the objective, which
was to determine the risks and benefits of expectant management
versus planned early delivery for the hypertensive disorders of preg-
nancy after 34 weeks gestation. Themanagement of pre-eclampsia
diagnosed before 34 weeks is described in another Cochrane Re-
view (Churchill 2013). The majority of women included in this
review had mild pre-eclampsia and gestational hypertension, with
fewer women having chronic hypertension. Most of the women
included came from the Netherlands, with smaller numbers from
India, USA and Saudi Arabia, making the review globally applica-
ble. The results are applicable to general obstetric practice when
the hypertensive disorders of pregnancy are considered together,
but an individual patient meta-analysis may provide more answers
as it would allow for more statistical power when reviewing the
different types of hypertensive disorders in pregnancy.
Quality of the evidence
Two fairly large, well-designed trials contributed the majority of
the evidence to this review (Broekhuijsen 2015; Koopmans 2009).
Due to the nature of the intervention, no studies attempted to
blind participants or clinicians to group allocation. We did not
downgrade studies for this; however, women and staff would have
been aware of the intervention and this may have affected aspects
of care and decision-making, for example, whether to carry out a
caesarean section.
We graded the level of evidence as high (composite maternal mor-
tality and morbidity), moderate (caesarean section, duration of
hospital stay after delivery formother, and duration of hospital stay
after delivery for baby), or low (composite infant mortality and
morbidity) (see Summary of findings for the main comparison).
Where the evidence was downgraded, it was mostly because the
CIs were wide, crossing both the line of no effect and appreciable
benefit or harm.
Potential biases in the review process
The assessment of risk of bias involves subjective judgements. This
potential limitation is minimised by following the procedures in
the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011), with review authors independently assessing stud-
ies and resolving any disagreement through discussion, and if re-
quired involving a third assessor in the decision.
Agreements and disagreements with other
studies or reviews
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The findings of this review show that planned early delivery for
hypertensive disorders of pregnancy are associated with less severe
maternal adverse outcomes. This analysis looks at all the hyperten-
sive diseases, namely chronic hypertension, gestational hyperten-
sion and mild pre-eclampsia as one group. The National Institute
for Health and Clinical Excellence guidelines on hypertension in
pregnancy: diagnosis and management (NICE 2010), the Amer-
ican College of Obstetricians and the Society for Maternal-Fetal
Medicine and Gynecologists Committee opinion number 560 on
medically indicated late-preterm and early term deliveries (ACOG
No. 560 2013) and the Society of Obstetric Medicine of Australia
and New Zealand guideline for the management of hypertensive
disorders of pregnancy (Lowe 2014) set different gestational ages
for delivery based on the hypertensive condition.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For hypertensive disorders as a group, based on the limited data
available for this review, planned early delivery appears to be better
for the mother after 34 weeks’ gestation. However, it is unclear
whether planned early delivery increases risks for the baby, espe-
cially at earlier gestations, and more data are needed to guide prac-
tice. It is also unclear whether planned early delivery is advisable
for different hypertensive conditions. Further studies are needed
to look at the individual conditions before this is implemented
into clinical practice.
Implications for research
Further studies are needed to look at the different types of hyper-
tensive diseases and the optimal timing of delivery for these condi-
tions. These studies should include thematernal outcomes ofmor-
tality and severemorbidity like eclampsia, a cerebral vascular event,
pulmonary oedema, severe renal impairment, a liver haematoma
or rupture, liver failure,HELLP syndrome,DIC, thromboembolic
disease and abruptio placentae. Perinatal outcomes that should be
included are fetal or neonatal death, grade III or IV intraventric-
ular or intracerebral haemorrhage, NEC, ARDS or grade III/IV
hyaline membrane disease, small-for-gestational age and neonatal
seizures. The outcomes of the incidence of caesarean section, du-
ration of hospital stay after delivery for mother and duration of
hospital stay after delivery for baby should also be included.
An individual patient meta-analysis on the data currently available
would provide further information on the outcomes of the differ-
ent types of hypertensive disease encountered in pregnancy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Broekhuijsen 2015
Methods 2-arm multicentre randomised controlled trial.
Participants Setting: 51 hospitals in the Netherlands. June 2009 to March 2013.
Inclusion criteria: pregnant women (singleton or multiple pregnancies), 34+0-36+6
weeks’ gestation, who had gestational hypertension, mild pre-eclampsia, or deteriorating
chronic hypertension. Gestational hypertension: diastolic blood pressure ≥ 100 mmHg
on 2 occasions at least 6 hours apart in a woman who was normotensive until at least 20
weeks GA. Mild PE: diastolic blood pressure > 90 mmHg on 2 occasions at least 6 hours
apart in a woman who was normotensive until at least 20 weeks GA plus proteinuria (>
300 mg total protein in a 24-hour urine collection or > 30 in a spot urine protein:creati-
nine ratio). Chronic hypertension: diastolic blood pressure ≥ 90 mmHg on 2 occasions
at least 6 hours apart, diagnosed before 20 weeks of gestation
Women with singleton or multiple pregnancies are eligible, independent of the position
of the fetus (i.e. cephalic or breech). Neither diabetes mellitus, nor small-for-gestational
age nor a history of caesarean section are exclusion criteria
Exclusion criteria: diastolic blood pressure ≥ 110 mmHg despite medication, systolic
blood pressure ≥ 170 mmHg despite medication, proteinuria ≥ 5 g per 24 hours,
eclampsia, HELLP syndrome, pulmonary oedema or cyanosis, oliguria < 500 mL in 24
hours, renal disease, heart disease, HIV-positive, non-reassuring fetal heart rate, absent
flow or reversed flow in the umbilical artery, fetal abnormalities including an abnormal
karyotype, ruptured membranes and severe pre-eclamptic complaints such as frontal
headaches
Interventions Experimental intervention: planned early delivery with an induction of labour started
within 24 hours after randomisation
If vaginal delivery was not contraindicated and the cervix was considered favourable an
amniotomy was performed and augmentation with oxytocin was used if indicated. In
cases of unfavourable cervix, induction was preceded with cervical ripening according
to the local protocol. Prostaglandins were not administered to women with a history
of caesarean section and in these cases a Foley catheter, followed by amniotomy and
oxytocin were used instead
Where vaginal delivery is contraindicated (e.g. breech presentation or a history of 2
caesarean sections) the woman will be delivered by caesarean section within 24 hours
after randomisation. 353 women randomised (1 woman subsequently withdrew)
Control/Comparison intervention: expectant monitoring until 37 weeks of GA.Mon-
itored until the onset of spontaneous delivery. If labour had not started at 37 + 0 weeks,
labour was induced.Monitoring consisted of themother’s assessment of fetal movements,
electronic fetal heart rate monitoring at least twice a week and maternal blood pressure
measurement and screening of urine for protein. Intervention was recommended if the
fetal or maternal condition did not justify expectant monitoring any more, similar to
the exclusion criteria of the trial. 351 women randomised
Outcomes Composite adverse maternal outcome (eclampsia, HELLP syndrome, pulmonary
oedema, thromboembolic disease, placental abruption, and/or maternal death), neonatal
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Broekhuijsen 2015 (Continued)
morbidity, neonatal death
Funding source This trial was fundedbyZonMw,TheNetherlandsOrganisation forHealthResearch and
Development, programme Doelmatigheidsonderzoek (Health Care Efficiency Research,
grant 171102012)
Declarations of interest No conflicts of interests declared.
Notes Registered with the Netherlands Trial Register (NTR1792)
HWemailedDrKoopmans on6/8/15 to ask if the composite infant outcomeby gestation
at randomisation is available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done with a web-based
system by random permuted blocks with
variable block size (range 2 - 4), stratified
by centre
Allocation concealment (selection bias) Low risk Central allocation of women concealed al-
location
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study: “it is impossible to blind
the healthcare workers and patients in-
volved for the strategy to which the woman
is allocated”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessment does not appear to
have been blinded. Data were entered into
a web-based case report form, coded to en-
sure confidentiality
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women are accounted for. 1 woman
withdrew after being randomised to
planned early delivery. Analysis was by in-
tention-to-treat in Broekhuijsen 2014, but
not in Broekhuijsen 2015. A subset of 200
women received quality-of-life question-
naires. The results of this subset of women
are not included in this review
Selective reporting (reporting bias) Low risk All outcomes that were prespecified in the
protocol were reported
Other bias Low risk The baseline characteristics of women ran-
domly assigned to planned delivery and ex-
pectant monitoring appear to be similar.
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“When compared with randomly assigned
women, women who declined to be ran-
domly assigned more often finished higher
education, were more often non-smokers,
were more often nulliparous, and had a
lower GA. Otherwise, baseline characteris-
tics were much the same in randomly as-
signed andnot randomly assignedwomen”.
This may affect the generalisability of the
results of this study, but is not a source of
bias per se
Hamed 2014
Methods 2-arm randomised controlled trial.
Participants Setting: Saudi Arabia and Egypt.Maternity-ChildrenHospital, Al-Qassim region, Saudi
Arabia andWomen’sHealthCenter, Assiut University, Egypt. April 2012 -October 2013
Inclusion criteria: women with a singleton pregnancy with mild to moderate essential
chronic hypertension without proteinuria. GA at recruitment 24 - 36 weeks. Diastolic
blood pressure between 90 and 110 mmHg and/or systolic pressure between 140 and
160 mmHg on 2 occasions at least 6 hours apart in the first half of pregnancy or if the
woman was known to be hypertensive before pregnancy
Exclusion criteria: severe chronic hypertension (blood pressure ≥ 160/110 mmHg);
gestational hypertension; new onset pre-eclampsia in a previously normotensive woman;
secondary hypertension (excluded by examination and relevant investigations such as
kidney function tests, urine analysis, abdominal ultrasound, renal arteryDoppler, urinary
catecholamine, and autoimmune serologic profile); target organ damage excluded by
opthalmological fundus examination, and renal and cardiac assessment; and medical or
obstetric risk factors such as malpresentation at recruitment, placenta previa, uterine
scar, fetal anomalies, or pregestational diabetes mellitus
Interventions Experimental intervention: delivery at 37 completed weeks, provided that no maternal
or fetal complications demanded elective preterm labour. If the Bishop score was > 8,
labour was induced by oxytocin infusion and amniotomy. If the Bishop score was 8 or
less, cervical ripening was induced by vaginal misoprostol at a dose of 50 µg every 6
hours up to a maximum of 200 µg, followed by an oxytocin infusion and amniotomy
Women continued any antihypertensive drugs that they used before recruitment, and the
dose was monitored to achieve control of blood pressure. 38 women were randomised
Control/Comparison intervention: expectantmanagement until the spontaneous onset
of labour or 41 gestational weeks
Monitored as outpatients for blood pressure measurement with dipstick screening for
proteinuria 2 - 3 times per week.Hospitalised during the initial evaluation and ifmaternal
or fetal complications developed
Women continued any antihypertensive drugs that they used before recruitment, and the
dose was monitored to achieve control of blood pressure. 38 women were randomised
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Outcomes Superimposed pre-eclampsia, severe hypertension, pretermdelivery, placental abruption,
oligohydramnios, intrauterine growth restriction, perinatal mortality, GA at delivery,
birthweight, caesarean section, neonatal intensive care unit admission
Funding source The authors acknowledge the Deanship of Scientific Research in Qassim University for
financial support for this work through an official grant (research number 1681/1433-
1434)
Declarations of interest No conflicts of interests declared.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible women were randomised by a computer-
generated table, and allocated by 1:1 ratio to group
A or group B
Allocation concealment (selection bias) Unclear risk No description of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and personnel was not
possible. This may have had an effect on other
treatment decisions
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessment does not appear to have been
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up reported on flow diagram
Selective reporting (reporting bias) Unclear risk Reporting appeared to be good; however no pro-
tocol was available to assess whether all prespeci-
fied outcomes were reported
Other bias Low risk The groups appear to be comparable at baseline
Koopmans 2009
Methods 2-arm multicentre randomised controlled trial
Participants Setting: 38hospitals (6 academic and32non-academic) inNetherlands betweenOctober
2005 and March 2008
Inclusion criteria: women with a singleton pregnancy at 36 (0 days) - 41 weeks (0
days) gestation who had gestational hypertension or mild pre-eclampsia. Gestational
hypertension was defined as diastolic blood pressure of 95 mmHg or higher measured
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on 2 occasions at least 6 hours apart. Mild pre-eclampsia was defined as diastolic blood
pressure of 90mmHg or highermeasured on 2 occasions at least 6 hours apart, combined
with proteinuria (2 or more occurrences of protein on a dipstick, > 300 mg total protein
within a 24-hour urine collection, or ratio of protein to creatinine > 30 mg/mmol)
Exclusion criteria: severe gestational hypertension or severe pre-eclampsia, defined as
systolic blood pressure of 170 mmHg or higher, diastolic blood pressure of 110 mmHg
or higher, or proteinuria of 5 g or higher per 24 hours. Other exclusion criteria: pre-
existing hypertension treated with antihypertensive drugs, diabetes mellitus, gestational
diabetes needing insulin treatment, renal disease, heart disease, previous caesarean sec-
tion, HELLP syndrome, oliguria of less than 500 mL per 24 hours, pulmonary oedema
or cyanosis, HIV seropositivity, use of intravenous antihypertensive drugs, fetal anoma-
lies, suspected intrauterine growth restriction, abnormalities detected during fetal-heart-
rate monitoring, non-vertex position
Interventions Experimental intervention: induction of labour within 24 hours of randomisation. If
the Bishop score was > 6, labour was induced with amniotomy and if needed augmen-
tation with oxytocin. If the Bishop score was ≤ 6, cervical ripening was stimulated with
intracervical or intravaginal prostaglandins or a balloon catheter. Use of oxytocin or
prostaglandins depended on local protocols. 377 women randomised
Control/Comparison intervention: expectant monitoring. They were monitored until
the onset of spontaneous delivery, in hospital or outpatient setting, depending on the
condition of the woman with frequent blood pressure measurements and testing of urine
for protein of the mother. Fetal monitoring included movements as reported by the
mother, electronic fetal-heart-rate monitoring and ultrasound examination. Induction
of labour was recommended if the systolic blood pressure was 170 mmHG or higher
or if the diastolic blood pressure was 110 mmHg or higher, if there was proteinuria of
5 g or higher per 24 hours, if eclampsia developed, if HELLP syndrome was present, if
there was suspected fetal distress, if prelabour rupture of membranes lasting more than
48 hours occurred, if there was meconium-stained amniotic fluid, or a fetus with GA
beyond 41 weeks. 379 women randomised
Outcomes Composite of poor maternal outcome which included maternal mortality, maternal
morbidity (eclampsia, HELLP syndrome, pulmonary oedema, thromboembolic disease,
and placental abruption), progression to severe hypertension or proteinuria and a major
postpartum haemorrhage (> 1000 mL blood loss)
Funding source This trial was funded by ZonMw, the Netherlands organisation for health research and
development, programme Doelmatigheidsonderzoek (grant number 945-06-553)
Declarations of interest No conflicts of interests declared.
Notes HW emailed Dr Koopmans on 6/8/15 to ask if the mean and standard deviation are
available for continuous variables (e.g. duration of hospital stay after delivery, economic
outcomes), reported in publications as median and IQR. Also, whether health-related
quality of life measures are available in a form that could be used in the review
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Good random sequence generation. Block
randomisation with a variable block size of
2 - 8. Web-based application used to strat-
ify for centre, parity, and hypertensive-re-
lated disease (gestational hypertension or
pre-eclampsia). Women were randomly al-
located in a 1:1 ratio to receive either in-
duction of labour or expectant monitoring
Allocation concealment (selection bias) Low risk Central allocation using a web-based appli-
cation.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “in this open-label trial, masking of partic-
ipants, obstetricians and outcome assessors
was not possible for allocation of the ran-
domisation number or intervention.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “in this open-label trial, masking of partic-
ipants, obstetricians and outcome assessors
was not possible for allocation of the ran-
domisation number or intervention.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk The analysis was by intention-to-treat.
Data are reported for all randomised
women
Fewer women participated in the quality of
life study (questionnaires were not available
for 217 women. 48/539 did not respond to
the questionnaire, giving a 91% response
rate)
Selective reporting (reporting bias) Low risk All outcomes that were prespecified in the
protocol were reported
Other bias Low risk The groups appear to be comparable at
baseline. The report states that the fun-
der “had no role in study design, data col-
lection, data analysis, data interpretation,
writing of the report, or the decision to sub-
mit the paper for publication”
Majeed 2014
Methods 2-arm randomised controlled trial.
Participants Setting: May 2011 to April 2012 in Government Medical College, Kolkata, India
Inclusion criteria: pregnant women at 36 - 40weeks’ gestation, withmild pre-eclampsia/
gestational hypertension without proteinuria. A diagnosis of gestational hypertension
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was made if systolic blood pressure ≥ 140 or diastolic blood pressure ≥ 90 mmHg for
the first time during pregnancy without proteinuria. A diagnosis of mild pre-eclampsia
was made if systolic blood pressure was 140 - 159 mmHg and diastolic blood pressure
is 90 - 109 mmHg accompanied by proteinuria of > 0.3 g to < 5 g/24 hours
Exclusion criteria: not described
Interventions Experimental intervention: induction of labour (no further information)
Control/Comparison intervention: expectant management (no further information)
100 women were randomised. The number of women in each group is not stated, so we
assume it was 50, as women were randomised in a 1:1 manner
Outcomes Maternal: severe hypertension, severe proteinuria, eclampsia, placental abruption,
HELLP syndrome, disseminated intravascular coagulation, postpartum haemorrhage,
retinal haemorrhage, pulmonary oedema. Caesarean section. Admission to delivery in-
terval. Hospital stay.
Perinatal: asphyxia, respiratory distress syndrome, very low birthweight, meconium as-
piration, mechanical ventilation, neonatal intensive care unit admission
Funding source No information given - abstract only.
Declarations of interest No information given - abstract only.
Notes This trial report was in abstract form only (which could explain the paucity of detail)
HW emailed Professor Singh on 30/4/15 and 5/8/15, asking:
How many women were recruited to each group?
Please would you describe the process of randomisation and group allocation
Would you be able to provide data on any of the following outcomes (review outcomes
listed)
No reply received at present.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States that women were “randomized in 1:1 man-
ner”, but no information on the method
Allocation concealment (selection bias) Unclear risk No description
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It was not possible to blind participants and per-
sonnel to whether they had been assigned to in-
duction of labour or expectant management
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment mentioned
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Majeed 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The number of women allocated to each group is
not reported, so it is not possible to assess whether
data for all women have been reported
Selective reporting (reporting bias) High risk Only outcomes with significant differences be-
tween groups were reported
Other bias Low risk The report states that the groups were comparable
at baseline
Owens 2014
Methods 2-arm randomised control trial.
Participants Setting: women admitted toTheWiserHospital forWomen and Infants at theUniversity
of Mississippi Medical Center (UMMC) from March 2002 to June 2009
Inclusion criteria: pregnant women with mild pre-eclampsia, 34 - 37 weeks (with esti-
mated fetal weight > 2000 g), no othermaternal-fetal-pregnancy complications. (ACOG
2002 criteria for mild pre-eclampsia.) No maternal or fetal contraindications to conser-
vative management. Age 18 - 50
Exclusion criteria: non-gestational diabetes, chronic hypertension, severe pre-eclamp-
sia, non-reassuring fetal assessment intrauterine growth restriction fetal anomalies, mul-
tiple gestation, premature preterm rupture of membranes, placenta previa, unexplained
vaginal bleeding, antihypertensive use, current gestation poor dating, contraindication
to conservative management, active labour at admission
Interventions Experimental intervention: planned early delivery via induction of labour or caesarean
delivery within 12 hours of randomisation
All study participants were treated with magnesium sulphate prophylaxis intrapartum
and immediately postpartum
97 women were randomised, 3 were subsequently excluded for not meeting the inclusion
criteria
Control/Comparison intervention: inpatient expectantmanagement, to 37 weeks’ ges-
tation unless there was spontaneous onset of labour or rupture of membranes, suspected
placental abruption, development of severe PE of fetal compromise. All study partici-
pants were treated with magnesium sulphate prophylaxis intrapartum and immediately
postpartum
86 women were randomised (11 were subsequently excluded for not meeting the inclu-
sion criteria (7), voluntarily withdrawing from the study (1), and leaving the hospital
(3))
Outcomes Primary: maternal morbidity, mortality, and development of severe pre-eclampsia. Sec-
ondary: major neonatal morbidities and mortality
Funding source Funded by Division of Maternal-fetal Medicine in the Department of Obstetrics and
Gynaecology, University of Mississippi Medical Centre
Declarations of interest No conflicts of interests declared.
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Owens 2014 (Continued)
Notes ClinicalTrials.gov: NCT00789919
HW emailed Professor Owens on 11/8/15, asking how the random sequence was gen-
erated, if composite maternal and infant outcomes were available, and for duration of
infant stay after delivery. No response was received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised using stratified and random permuted
blocks of 2 in consecutively numbered opaque en-
velopes. However, the sequence generation was not
described
Allocation concealment (selection bias) Low risk Opaque envelopes concealed allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It was not possible to blind participants and personnel
to whether they had been assigned to induction of
labour or expectant management
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The analysis was not intention-to-treat. 3 (out of 97)
participants left the planned early delivery group, and
11 (out of 86) left the expectant management group,
and were excluded from the analyses
Selective reporting (reporting bias) Low risk The outcomes prespecified in the protocol were re-
ported
Other bias Unclear risk The study was stopped early, at 74% of the enrol-
ment target, when hospital policy changed to discour-
age inpatient hospitalisation for ”uncomplicatedmild
preterm preeclampsia”. This left the study under-
powered to demonstrate statistically significant dif-
ferences
GA gestational age
HELLP: haemolysis, elevated liver enzymes and low platelet count
IQR: interquartile range
PE: pre-eclampsia
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ramrakhyani 2001 Not a randomised controlled trial. No randomisation. Group allocation based on gestational age at presentation
Tukur 2007 Comparing planned early delivery by caesarean section with planned early delivery by induction with vaginal
misoprostol
Characteristics of ongoing studies [ordered by study ID]
Shennan 2013
Trial name or title PHOENIX - Pre-eclampsia in HOspital: Early iNductIon or eXpectant management
Methods 2-arm trial. “randomly allocated”, no description of method of randomisation in trial registration
Participants Pregnant women with pre-eclampsia between 34 and 37 weeks of gestation
Interventions Experimental intervention: planned early birth. Induced within 48 hours of group allocation
Control/Comparison intervention: monitored in hospital. Inpatient until 37 weeks then induced
Outcomes Maternal morbidity, perinatal mortality, neurodevelopmental assessment at age 2
Starting date April 2014. Anticipated to take approximately 3 years to recruit 900 women
Contact information Professor Andrew Shennan (andrew.shennan@kcl.ac.uk)
Notes ISRCTN01879376
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D A T A A N D A N A L Y S E S
Comparison 1. Planned early delivery versus expectant management (all women)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Composite maternal mortality
and morbidity
2 1459 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.57, 0.83]
2 Composite infant mortality and
morbidity
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Maternal mortality 2 1457 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Eclampsia 2 1459 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.14]
5 Pulmonary oedema 2 1459 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.17]
6 Severe renal impairment 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.14, 0.92]
7 HELLP syndrome 3 1628 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.17, 0.93]
8 Thromboembolic disease 2 1459 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.22, 12.58]
9 Abruptio placentae 3 1535 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.17, 2.34]
10 Postpartum haemorrhage 1 741 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.57, 1.35]
11 Severe hypertension 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12 Caesarean section 4 1728 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.78, 1.07]
13 Assisted delivery
(ventouse/forceps)
2 1459 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.70, 1.24]
14 Maternal morbidity of
caesarean section
1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.17, 3.35]
14.1 Endometritis 1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.17, 3.35]
15 Maternal morbidity related to
induction of labour
1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.1 Uterine rupture 1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Admission to a high care or
intensive care unit
1 708 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.16, 1.07]
17 Fetal death 1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Neonatal death 3 1535 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.14]
19 Grade III or IV intraventricular
or intracerebral haemorrhage
1 674 Risk Ratio (M-H, Fixed, 95% CI) 6.92 [0.36, 133.41]
20 Nectrotising enterocolitis 2 1338 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.14, 6.89]
21 Respiratory distress syndrome 3 1511 Risk Ratio (M-H, Fixed, 95% CI) 2.24 [1.20, 4.18]
22 Small-for-gestational age 3 1001 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [0.89, 2.79]
23 Neonatal seizures 1 699 Risk Ratio (M-H, Fixed, 95% CI) 3.97 [0.45, 35.30]
24 Apgar score less than seven at
five minutes
2 1454 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.60, 2.05]
25 Cord blood pH less than 7.1 or
as defined by trial authors
2 1145 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.31, 1.09]
26 Surfactant use 1 639 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
27 Neonatal intensive care unit or
high care unit admission
4 1585 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [1.13, 2.40]
28 Early neonatal sepsis 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
29 Duration of hospital stay after
delivery for mother (days)
2 925 Mean Difference (IV, Fixed, 95% CI) -0.16 [-0.46, 0.15]
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30 Duration of hospital stay after
delivery for baby (days)
1 756 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.57, 0.17]
Comparison 2. Planned early delivery versus expectant management (by gestational age)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Composite maternal mortality
and morbidity
2 1459 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.57, 0.83]
1.1 34 + 0 to 36 + 6 weeks GA
at randomisation
2 778 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.48, 1.24]
1.2 37 + 0 to 38 + 6 weeks GA
at randomisation
1 380 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.53, 0.90]
1.3 39 + 0 to 41 + 0 weeks GA
at randomisation
1 301 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.47, 0.88]
2 Respiratory distress syndrome 2 1459 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [1.16, 5.55]
2.1 34 + 0 to 36 + 6 weeks GA
at randomisation
2 778 Risk Ratio (M-H, Fixed, 95% CI) 3.32 [1.35, 8.18]
2.2 37 + 0 to 38 + 6 weeks GA
at randomisation
1 380 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.72]
2.3 39 + 0 to 41 + 0 weeks GA
at randomisation
1 301 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.07, 17.74]
3 Composite infant mortality and
morbidity
1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.46, 1.28]
3.1 36 + 0 to 36 + 6 weeks GA
at randomisation
1 75 Risk Ratio (M-H, Fixed, 95% CI) 2.63 [0.29, 24.10]
3.2 37 + 0 to 38 + 6 weeks GA
at randomisation
1 380 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.31, 1.49]
3.3 39 + 0 to 41 + 0 weeks GA
at randomisation
1 301 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.35, 1.49]
Comparison 3. Planned early delivery versus expectant management (by each gestational week)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Composite maternal mortality
and morbidity
2 1459 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.57, 0.83]
1.1 34 + 0 to 34 + 6 weeks GA
at randomisation
1 154 Risk Ratio (M-H, Fixed, 95% CI) 4.75 [0.23, 97.34]
1.2 35 + 0 to 35 + 6 weeks GA
at randomisation
1 236 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.10]
1.3 36 + 0 to 36 + 6 weeks GA
at randomisation
2 388 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.59, 1.62]
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1.4 37 + 0 to 37 + 6 weeks GA
at randomisation
1 188 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.52, 1.08]
1.5 38 + 0 to 38 + 6 weeks GA
at randomisation
1 192 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.43, 0.94]
1.6 39 + 0 to 39 + 6 weeks GA
at randomisation
1 186 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.53, 1.14]
1.7 40 + 0 to 41 + 0 weeks GA
at randomisation
1 115 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.26, 0.79]
2 Respiratory distress syndrome 1 703 Risk Ratio (M-H, Fixed, 95% CI) 3.32 [1.38, 8.01]
2.1 34 + 0 to 34 + 6 weeks GA
at randomisation
1 154 Risk Ratio (M-H, Fixed, 95% CI) 2.37 [0.78, 7.24]
2.2 35 + 0 to 35 + 6 weeks GA
at randomisation
1 236 Risk Ratio (M-H, Fixed, 95% CI) 7.62 [0.93, 62.27]
2.3 36 + 0 to 36 + 6 weeks GA
at randomisation
1 313 Risk Ratio (M-H, Fixed, 95% CI) 3.41 [0.39, 30.15]
3 Composite infant mortality and
morbidity
1 756 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.46, 1.29]
3.1 36 + 0 to 36 + 6 weeks GA
at randomisation
1 75 Risk Ratio (M-H, Fixed, 95% CI) 2.63 [0.29, 24.10]
3.2 37 + 0 to 37 + 6 weeks GA
at randomisation
1 188 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.17, 1.35]
3.3 38 + 0 to 38 + 6 weeks GA
at randomisation
1 192 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.33, 4.24]
3.4 39 + 0 to 39 + 6 weeks GA
at randomisation
1 186 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.32, 1.95]
3.5 40 + 0 to 41 + 0 weeks GA
at randomisation
1 115 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.19, 2.12]
Comparison 4. Planned early delivery versus expectant management (by condition)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Composite maternal mortality
and morbidity
2 1445 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.58, 0.85]
1.1 Gestational hypertension 2 678 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.61, 1.00]
1.2 Mild pre-eclampsia 2 570 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.45, 0.81]
1.3 Chronic hypertension 1 197 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.10, 2.86]
2 Respiratory distress syndrome 1 703 Risk Ratio (M-H, Fixed, 95% CI) 3.36 [1.36, 8.31]
2.1 Gestational hypertension 1 182 Risk Ratio (M-H, Fixed, 95% CI) 3.91 [0.45, 34.34]
2.2 Mild pre-eclampsia 1 324 Risk Ratio (M-H, Fixed, 95% CI) 4.82 [1.07, 21.65]
2.3 Chronic hypertension 1 197 Risk Ratio (M-H, Fixed, 95% CI) 2.15 [0.55, 8.35]
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Analysis 1.1. Comparison 1 Planned early delivery versus expectant management (all women), Outcome 1
Composite maternal mortality and morbidity.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 1 Composite maternal mortality and morbidity
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 4/352 11/351 6.2 % 0.36 [ 0.12, 1.13 ]
Koopmans 2009 117/377 166/379 93.8 % 0.71 [ 0.59, 0.86 ]
Total (95% CI) 729 730 100.0 % 0.69 [ 0.57, 0.83 ]
Total events: 121 (Delivery), 177 (Expectant)
Heterogeneity: Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 3.94 (P = 0.000083)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours delivery Favours expectant
Analysis 1.2. Comparison 1 Planned early delivery versus expectant management (all women), Outcome 2
Composite infant mortality and morbidity.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 2 Composite infant mortality and morbidity
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Broekhuijsen 2015 20/352 6/351 3.32 [ 1.35, 8.18 ]
Koopmans 2009 24/377 32/379 0.75 [ 0.45, 1.26 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours delivery Favours expectant
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Analysis 1.3. Comparison 1 Planned early delivery versus expectant management (all women), Outcome 3
Maternal mortality.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 3 Maternal mortality
Study or subgroup Delivery
Expectant
Manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 0/352 0/351 Not estimable
Koopmans 2009 0/377 0/377 Not estimable
Total (95% CI) 729 728 Not estimable
Total events: 0 (Delivery), 0 (Expectant Management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours delivery Favours expectant
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Analysis 1.4. Comparison 1 Planned early delivery versus expectant management (all women), Outcome 4
Eclampsia.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 4 Eclampsia
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 0/352 2/351 100.0 % 0.20 [ 0.01, 4.14 ]
Koopmans 2009 0/377 0/379 Not estimable
Total (95% CI) 729 730 100.0 % 0.20 [ 0.01, 4.14 ]
Total events: 0 (Delivery), 2 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours delivery Favours expectant
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Analysis 1.5. Comparison 1 Planned early delivery versus expectant management (all women), Outcome 5
Pulmonary oedema.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 5 Pulmonary oedema
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 0/352 0/351 Not estimable
Koopmans 2009 0/377 2/379 100.0 % 0.20 [ 0.01, 4.17 ]
Total (95% CI) 729 730 100.0 % 0.20 [ 0.01, 4.17 ]
Total events: 0 (Delivery), 2 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours delivery Favours expectant
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Analysis 1.6. Comparison 1 Planned early delivery versus expectant management (all women), Outcome 6
Severe renal impairment.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 6 Severe renal impairment
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Majeed 2014 (1) 5/50 14/50 100.0 % 0.36 [ 0.14, 0.92 ]
Total (95% CI) 50 50 100.0 % 0.36 [ 0.14, 0.92 ]
Total events: 5 (Delivery), 14 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours delivery Favours expectant
(1) Acute renal failure
43Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 Planned early delivery versus expectant management (all women), Outcome 7
HELLP syndrome.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 7 HELLP syndrome
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 3/352 6/351 32.2 % 0.50 [ 0.13, 1.98 ]
Koopmans 2009 4/377 11/379 58.8 % 0.37 [ 0.12, 1.14 ]
Owens 2014 0/94 1/75 8.9 % 0.27 [ 0.01, 6.45 ]
Total (95% CI) 823 805 100.0 % 0.40 [ 0.17, 0.93 ]
Total events: 7 (Delivery), 18 (Expectant management)
Heterogeneity: Chi2 = 0.18, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.14 (P = 0.033)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours delivery Favours expectant
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Analysis 1.8. Comparison 1 Planned early delivery versus expectant management (all women), Outcome 8
Thromboembolic disease.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 8 Thromboembolic disease
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 1/352 1/351 66.8 % 1.00 [ 0.06, 15.88 ]
Koopmans 2009 1/377 0/379 33.2 % 3.02 [ 0.12, 73.80 ]
Total (95% CI) 729 730 100.0 % 1.67 [ 0.22, 12.58 ]
Total events: 2 (Delivery), 1 (Expectant management)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours delivery Favours expectant
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Analysis 1.9. Comparison 1 Planned early delivery versus expectant management (all women), Outcome 9
Abruptio placentae.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 9 Abruptio placentae
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 0/352 2/351 45.5 % 0.20 [ 0.01, 4.14 ]
Hamed 2014 3/38 3/38 54.5 % 1.00 [ 0.22, 4.65 ]
Koopmans 2009 0/377 0/379 Not estimable
Total (95% CI) 767 768 100.0 % 0.64 [ 0.17, 2.34 ]
Total events: 3 (Delivery), 5 (Expectant management)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours delivery Favours expectant
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Analysis 1.10. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
10 Postpartum haemorrhage.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 10 Postpartum haemorrhage
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Koopmans 2009 35/370 40/371 100.0 % 0.88 [ 0.57, 1.35 ]
Total (95% CI) 370 371 100.0 % 0.88 [ 0.57, 1.35 ]
Total events: 35 (Delivery), 40 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours delivery Favours expectant
Analysis 1.11. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
11 Severe hypertension.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 11 Severe hypertension
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hamed 2014 (1) 5/38 3/38 1.67 [ 0.43, 6.49 ]
Koopmans 2009 (2) 62/373 103/377 0.61 [ 0.46, 0.81 ]
Owens 2014 (3) 3/94 20/75 0.12 [ 0.04, 0.39 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours delivery Favours expectant
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(1) blood pressure >=160/110mm Hg
(2) diastolic blood pressure >110mm Hg
(3) systolic >160mm Hg or diastolic >110mm Hg on two occasions at least 4 hours apart
Analysis 1.12. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
12 Caesarean section.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 12 Caesarean section
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 107/352 114/351 49.4 % 0.94 [ 0.75, 1.16 ]
Koopmans 2009 54/377 72/379 31.1 % 0.75 [ 0.55, 1.04 ]
Majeed 2014 12/50 14/50 6.1 % 0.86 [ 0.44, 1.66 ]
Owens 2014 42/94 28/75 13.5 % 1.20 [ 0.83, 1.73 ]
Total (95% CI) 873 855 100.0 % 0.91 [ 0.78, 1.07 ]
Total events: 215 (Delivery), 228 (Expectant management)
Heterogeneity: Chi2 = 3.51, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
13 Assisted delivery (ventouse/forceps).
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 13 Assisted delivery (ventouse/forceps)
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 32/352 34/351 38.7 % 0.94 [ 0.59, 1.49 ]
Koopmans 2009 50/377 54/379 61.3 % 0.93 [ 0.65, 1.33 ]
Total (95% CI) 729 730 100.0 % 0.93 [ 0.70, 1.24 ]
Total events: 82 (Delivery), 88 (Expectant management)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
14 Maternal morbidity of caesarean section.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 14 Maternal morbidity of caesarean section
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Endometritis
Koopmans 2009 3/377 4/379 100.0 % 0.75 [ 0.17, 3.35 ]
Total (95% CI) 377 379 100.0 % 0.75 [ 0.17, 3.35 ]
Total events: 3 (Delivery), 4 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
15 Maternal morbidity related to induction of labour.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 15 Maternal morbidity related to induction of labour
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Uterine rupture
Koopmans 2009 0/377 0/379 Not estimable
Total (95% CI) 377 379 Not estimable
Total events: 0 (Delivery), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 1.16. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
16 Admission to a high care or intensive care unit.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 16 Admission to a high care or intensive care unit
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Koopmans 2009 6/360 14/348 100.0 % 0.41 [ 0.16, 1.07 ]
Total (95% CI) 360 348 100.0 % 0.41 [ 0.16, 1.07 ]
Total events: 6 (Delivery), 14 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
17 Fetal death.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 17 Fetal death
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Koopmans 2009 0/377 0/379 Not estimable
Total (95% CI) 377 379 Not estimable
Total events: 0 (Delivery), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
18 Neonatal death.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 18 Neonatal death
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 0/352 0/351 Not estimable
Hamed 2014 (1) 2/38 1/38 100.0 % 2.00 [ 0.19, 21.14 ]
Koopmans 2009 0/377 0/379 Not estimable
Total (95% CI) 767 768 100.0 % 2.00 [ 0.19, 21.14 ]
Total events: 2 (Delivery), 1 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
19 Grade III or IV intraventricular or intracerebral haemorrhage.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 19 Grade III or IV intraventricular or intracerebral haemorrhage
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 (1) 3/339 0/335 100.0 % 6.92 [ 0.36, 133.41 ]
Total (95% CI) 339 335 100.0 % 6.92 [ 0.36, 133.41 ]
Total events: 3 (Delivery), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
20 Nectrotising enterocolitis.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 20 Nectrotising enterocolitis
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 1/351 0/348 24.8 % 2.97 [ 0.12, 72.76 ]
Koopmans 2009 0/325 1/314 75.2 % 0.32 [ 0.01, 7.88 ]
Total (95% CI) 676 662 100.0 % 0.98 [ 0.14, 6.89 ]
Total events: 1 (Delivery), 1 (Expectant management)
Heterogeneity: Chi2 = 0.93, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
21 Respiratory distress syndrome.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 21 Respiratory distress syndrome
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 20/352 6/351 43.9 % 3.32 [ 1.35, 8.18 ]
Koopmans 2009 1/325 1/314 7.4 % 0.97 [ 0.06, 15.38 ]
Owens 2014 11/94 6/75 48.7 % 1.46 [ 0.57, 3.77 ]
Total (95% CI) 771 740 100.0 % 2.24 [ 1.20, 4.18 ]
Total events: 32 (Delivery), 13 (Expectant management)
Heterogeneity: Chi2 = 1.87, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.54 (P = 0.011)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
22 Small-for-gestational age.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 22 Small-for-gestational age
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hamed 2014 (1) 6/38 4/38 23.9 % 1.50 [ 0.46, 4.89 ]
Koopmans 2009 (2) 3/377 0/379 3.0 % 7.04 [ 0.36, 135.77 ]
Owens 2014 19/94 11/75 73.1 % 1.38 [ 0.70, 2.71 ]
Total (95% CI) 509 492 100.0 % 1.58 [ 0.89, 2.79 ]
Total events: 28 (Delivery), 15 (Expectant management)
Heterogeneity: Chi2 = 1.14, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 1.23. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
23 Neonatal seizures.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 23 Neonatal seizures
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 (1) 4/351 1/348 100.0 % 3.97 [ 0.45, 35.30 ]
Total (95% CI) 351 348 100.0 % 3.97 [ 0.45, 35.30 ]
Total events: 4 (Delivery), 1 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 1.24. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
24 Apgar score less than seven at five minutes.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 24 Apgar score less than seven at five minutes
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 14/351 10/350 52.8 % 1.40 [ 0.63, 3.10 ]
Koopmans 2009 7/374 9/379 47.2 % 0.79 [ 0.30, 2.09 ]
Total (95% CI) 725 729 100.0 % 1.11 [ 0.60, 2.05 ]
Total events: 21 (Delivery), 19 (Expectant management)
Heterogeneity: Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
25 Cord blood pH less than 7.1 or as defined by trial authors.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 25 Cord blood pH less than 7.1 or as defined by trial authors
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 (1) 6/270 6/263 23.9 % 0.97 [ 0.32, 2.98 ]
Koopmans 2009 (2) 9/311 19/301 76.1 % 0.46 [ 0.21, 1.00 ]
Total (95% CI) 581 564 100.0 % 0.58 [ 0.31, 1.09 ]
Total events: 15 (Delivery), 25 (Expectant management)
Heterogeneity: Chi2 = 1.18, df = 1 (P = 0.28); I2 =15%
Test for overall effect: Z = 1.69 (P = 0.091)
Test for subgroup differences: Not applicable
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(1) less than 7.05
(2) less than 7.05
Analysis 1.26. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
26 Surfactant use.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 26 Surfactant use
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Koopmans 2009 0/325 0/314 Not estimable
Total (95% CI) 325 314 Not estimable
Total events: 0 (Delivery), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.27. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
27 Neonatal intensive care unit or high care unit admission.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 27 Neonatal intensive care unit or high care unit admission
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 26/352 13/350 32.8 % 1.99 [ 1.04, 3.81 ]
Hamed 2014 12/38 3/38 7.5 % 4.00 [ 1.23, 13.05 ]
Koopmans 2009 10/324 8/314 20.4 % 1.21 [ 0.48, 3.03 ]
Owens 2014 20/94 14/75 39.2 % 1.14 [ 0.62, 2.10 ]
Total (95% CI) 808 777 100.0 % 1.65 [ 1.13, 2.40 ]
Total events: 68 (Delivery), 38 (Expectant management)
Heterogeneity: Chi2 = 4.31, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 2.62 (P = 0.0087)
Test for subgroup differences: Not applicable
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Analysis 1.28. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
28 Early neonatal sepsis.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 28 Early neonatal sepsis
Study or subgroup Delivery
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Broekhuijsen 2015 (1) 36/351 22/348 1.62 [ 0.97, 2.70 ]
Koopmans 2009 0/377 1/379 0.34 [ 0.01, 8.20 ]
Test for subgroup differences: Not applicable
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Analysis 1.29. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
29 Duration of hospital stay after delivery for mother (days).
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 29 Duration of hospital stay after delivery for mother (days)
Study or subgroup Delivery Expectant
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Koopmans 2009 377 1.6 (1.8) 379 1.9 (3.9) 50.3 % -0.30 [ -0.73, 0.13 ]
Owens 2014 (1) 94 3.1 (1.26) 75 3.11 (1.56) 49.7 % -0.01 [ -0.45, 0.43 ]
Total (95% CI) 471 454 100.0 % -0.16 [ -0.46, 0.15 ]
Heterogeneity: Chi2 = 0.86, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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(1) SD calculated from SE
Analysis 1.30. Comparison 1 Planned early delivery versus expectant management (all women), Outcome
30 Duration of hospital stay after delivery for baby (days).
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 1 Planned early delivery versus expectant management (all women)
Outcome: 30 Duration of hospital stay after delivery for baby (days)
Study or subgroup Delivery Expectant
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Koopmans 2009 377 2.5 (2.4) 379 2.7 (2.8) 100.0 % -0.20 [ -0.57, 0.17 ]
Total (95% CI) 377 379 100.0 % -0.20 [ -0.57, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Planned early delivery versus expectant management (by gestational age),
Outcome 1 Composite maternal mortality and morbidity.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 2 Planned early delivery versus expectant management (by gestational age)
Outcome: 1 Composite maternal mortality and morbidity
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 34 + 0 to 36 + 6 weeks GA at randomisation
Broekhuijsen 2015 4/352 11/351 6.3 % 0.36 [ 0.12, 1.13 ]
Koopmans 2009 18/40 15/35 9.1 % 1.05 [ 0.63, 1.75 ]
Subtotal (95% CI) 392 386 15.3 % 0.77 [ 0.48, 1.24 ]
Total events: 22 (Delivery), 26 (Expectant)
Heterogeneity: Chi2 = 3.09, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 1.08 (P = 0.28)
2 37 + 0 to 38 + 6 weeks GA at randomisation
Koopmans 2009 59/195 81/185 47.2 % 0.69 [ 0.53, 0.90 ]
Subtotal (95% CI) 195 185 47.2 % 0.69 [ 0.53, 0.90 ]
Total events: 59 (Delivery), 81 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 2.70 (P = 0.0070)
3 39 + 0 to 41 + 0 weeks GA at randomisation
Koopmans 2009 40/142 70/159 37.5 % 0.64 [ 0.47, 0.88 ]
Subtotal (95% CI) 142 159 37.5 % 0.64 [ 0.47, 0.88 ]
Total events: 40 (Delivery), 70 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 2.77 (P = 0.0056)
Total (95% CI) 729 730 100.0 % 0.68 [ 0.57, 0.83 ]
Total events: 121 (Delivery), 177 (Expectant)
Heterogeneity: Chi2 = 4.06, df = 3 (P = 0.26); I2 =26%
Test for overall effect: Z = 3.96 (P = 0.000074)
Test for subgroup differences: Chi2 = 0.41, df = 2 (P = 0.81), I2 =0.0%
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Analysis 2.2. Comparison 2 Planned early delivery versus expectant management (by gestational age),
Outcome 2 Respiratory distress syndrome.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 2 Planned early delivery versus expectant management (by gestational age)
Outcome: 2 Respiratory distress syndrome
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 34 + 0 to 36 + 6 weeks GA at randomisation
Broekhuijsen 2015 20/352 6/351 70.8 % 3.32 [ 1.35, 8.18 ]
Koopmans 2009 0/40 0/35 Not estimable
Subtotal (95% CI) 392 386 70.8 % 3.32 [ 1.35, 8.18 ]
Total events: 20 (Delivery), 6 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0089)
2 37 + 0 to 38 + 6 weeks GA at randomisation
Koopmans 2009 0/195 1/185 18.1 % 0.32 [ 0.01, 7.72 ]
Subtotal (95% CI) 195 185 18.1 % 0.32 [ 0.01, 7.72 ]
Total events: 0 (Delivery), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
3 39 + 0 to 41 + 0 weeks GA at randomisation
Koopmans 2009 1/142 1/159 11.1 % 1.12 [ 0.07, 17.74 ]
Subtotal (95% CI) 142 159 11.1 % 1.12 [ 0.07, 17.74 ]
Total events: 1 (Delivery), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Total (95% CI) 729 730 100.0 % 2.53 [ 1.16, 5.55 ]
Total events: 21 (Delivery), 8 (Expectant)
Heterogeneity: Chi2 = 2.31, df = 2 (P = 0.31); I2 =14%
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Chi2 = 2.31, df = 2 (P = 0.31), I2 =14%
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Analysis 2.3. Comparison 2 Planned early delivery versus expectant management (by gestational age),
Outcome 3 Composite infant mortality and morbidity.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 2 Planned early delivery versus expectant management (by gestational age)
Outcome: 3 Composite infant mortality and morbidity
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 36 + 0 to 36 + 6 weeks GA at randomisation
Koopmans 2009 3/40 1/35 3.4 % 2.63 [ 0.29, 24.10 ]
Subtotal (95% CI) 40 35 3.4 % 2.63 [ 0.29, 24.10 ]
Total events: 3 (Delivery), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
2 37 + 0 to 38 + 6 weeks GA at randomisation
Koopmans 2009 10/195 14/185 45.7 % 0.68 [ 0.31, 1.49 ]
Subtotal (95% CI) 195 185 45.7 % 0.68 [ 0.31, 1.49 ]
Total events: 10 (Delivery), 14 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
3 39 + 0 to 41 + 0 weeks GA at randomisation
Koopmans 2009 11/142 17/159 51.0 % 0.72 [ 0.35, 1.49 ]
Subtotal (95% CI) 142 159 51.0 % 0.72 [ 0.35, 1.49 ]
Total events: 11 (Delivery), 17 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Total (95% CI) 377 379 100.0 % 0.77 [ 0.46, 1.28 ]
Total events: 24 (Delivery), 32 (Expectant)
Heterogeneity: Chi2 = 1.30, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 1.30, df = 2 (P = 0.52), I2 =0.0%
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Analysis 3.1. Comparison 3 Planned early delivery versus expectant management (by each gestational
week), Outcome 1 Composite maternal mortality and morbidity.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 3 Planned early delivery versus expectant management (by each gestational week)
Outcome: 1 Composite maternal mortality and morbidity
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 34 + 0 to 34 + 6 weeks GA at randomisation
Broekhuijsen 2015 2/79 0/75 0.3 % 4.75 [ 0.23, 97.34 ]
Subtotal (95% CI) 79 75 0.3 % 4.75 [ 0.23, 97.34 ]
Total events: 2 (Delivery), 0 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
2 35 + 0 to 35 + 6 weeks GA at randomisation
Broekhuijsen 2015 1/104 9/132 4.5 % 0.14 [ 0.02, 1.10 ]
Subtotal (95% CI) 104 132 4.5 % 0.14 [ 0.02, 1.10 ]
Total events: 1 (Delivery), 9 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.061)
3 36 + 0 to 36 + 6 weeks GA at randomisation
Broekhuijsen 2015 1/169 2/144 1.2 % 0.43 [ 0.04, 4.65 ]
Koopmans 2009 18/40 15/35 9.1 % 1.05 [ 0.63, 1.75 ]
Subtotal (95% CI) 209 179 10.3 % 0.98 [ 0.59, 1.62 ]
Total events: 19 (Delivery), 17 (Expectant)
Heterogeneity: Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
4 37 + 0 to 37 + 6 weeks GA at randomisation
Koopmans 2009 32/96 41/92 23.8 % 0.75 [ 0.52, 1.08 ]
Subtotal (95% CI) 96 92 23.8 % 0.75 [ 0.52, 1.08 ]
Total events: 32 (Delivery), 41 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
5 38 + 0 to 38 + 6 weeks GA at randomisation
Koopmans 2009 27/99 40/93 23.5 % 0.63 [ 0.43, 0.94 ]
Subtotal (95% CI) 99 93 23.5 % 0.63 [ 0.43, 0.94 ]
Total events: 27 (Delivery), 40 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
6 39 + 0 to 39 + 6 weeks GA at randomisation
Koopmans 2009 27/83 43/103 21.8 % 0.78 [ 0.53, 1.14 ]
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(. . . Continued)
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 83 103 21.8 % 0.78 [ 0.53, 1.14 ]
Total events: 27 (Delivery), 43 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
7 40 + 0 to 41 + 0 weeks GA at randomisation
Koopmans 2009 13/59 27/56 15.8 % 0.46 [ 0.26, 0.79 ]
Subtotal (95% CI) 59 56 15.8 % 0.46 [ 0.26, 0.79 ]
Total events: 13 (Delivery), 27 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 2.78 (P = 0.0054)
Total (95% CI) 729 730 100.0 % 0.69 [ 0.57, 0.83 ]
Total events: 121 (Delivery), 177 (Expectant)
Heterogeneity: Chi2 = 9.49, df = 7 (P = 0.22); I2 =26%
Test for overall effect: Z = 3.87 (P = 0.00011)
Test for subgroup differences: Chi2 = 8.50, df = 6 (P = 0.20), I2 =29%
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Analysis 3.2. Comparison 3 Planned early delivery versus expectant management (by each gestational
week), Outcome 2 Respiratory distress syndrome.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 3 Planned early delivery versus expectant management (by each gestational week)
Outcome: 2 Respiratory distress syndrome
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 34 + 0 to 34 + 6 weeks GA at randomisation
Broekhuijsen 2015 10/79 4/75 67.7 % 2.37 [ 0.78, 7.24 ]
Subtotal (95% CI) 79 75 67.7 % 2.37 [ 0.78, 7.24 ]
Total events: 10 (Delivery), 4 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
2 35 + 0 to 35 + 6 weeks GA at randomisation
Broekhuijsen 2015 6/104 1/132 14.5 % 7.62 [ 0.93, 62.27 ]
Subtotal (95% CI) 104 132 14.5 % 7.62 [ 0.93, 62.27 ]
Total events: 6 (Delivery), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.058)
3 36 + 0 to 36 + 6 weeks GA at randomisation
Broekhuijsen 2015 4/169 1/144 17.8 % 3.41 [ 0.39, 30.15 ]
Subtotal (95% CI) 169 144 17.8 % 3.41 [ 0.39, 30.15 ]
Total events: 4 (Delivery), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 352 351 100.0 % 3.32 [ 1.38, 8.01 ]
Total events: 20 (Delivery), 6 (Expectant)
Heterogeneity: Chi2 = 0.95, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.67 (P = 0.0076)
Test for subgroup differences: Chi2 = 0.93, df = 2 (P = 0.63), I2 =0.0%
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Analysis 3.3. Comparison 3 Planned early delivery versus expectant management (by each gestational
week), Outcome 3 Composite infant mortality and morbidity.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 3 Planned early delivery versus expectant management (by each gestational week)
Outcome: 3 Composite infant mortality and morbidity
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 36 + 0 to 36 + 6 weeks GA at randomisation
Koopmans 2009 3/40 1/35 3.4 % 2.63 [ 0.29, 24.10 ]
Subtotal (95% CI) 40 35 3.4 % 2.63 [ 0.29, 24.10 ]
Total events: 3 (Delivery), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
2 37 + 0 to 37 + 6 weeks GA at randomisation
Koopmans 2009 5/96 10/92 32.5 % 0.48 [ 0.17, 1.35 ]
Subtotal (95% CI) 96 92 32.5 % 0.48 [ 0.17, 1.35 ]
Total events: 5 (Delivery), 10 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
3 38 + 0 to 38 + 6 weeks GA at randomisation
Koopmans 2009 5/99 4/93 13.1 % 1.17 [ 0.33, 4.24 ]
Subtotal (95% CI) 99 93 13.1 % 1.17 [ 0.33, 4.24 ]
Total events: 5 (Delivery), 4 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.81)
4 39 + 0 to 39 + 6 weeks GA at randomisation
Koopmans 2009 7/83 11/103 31.3 % 0.79 [ 0.32, 1.95 ]
Subtotal (95% CI) 83 103 31.3 % 0.79 [ 0.32, 1.95 ]
Total events: 7 (Delivery), 11 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
5 40 + 0 to 41 + 0 weeks GA at randomisation
Koopmans 2009 4/59 6/56 19.6 % 0.63 [ 0.19, 2.12 ]
Subtotal (95% CI) 59 56 19.6 % 0.63 [ 0.19, 2.12 ]
Total events: 4 (Delivery), 6 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 377 379 100.0 % 0.77 [ 0.46, 1.29 ]
Total events: 24 (Delivery), 32 (Expectant)
Heterogeneity: Chi2 = 2.50, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 2.50, df = 4 (P = 0.64), I2 =0.0%
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Analysis 4.1. Comparison 4 Planned early delivery versus expectant management (by condition), Outcome
1 Composite maternal mortality and morbidity.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 4 Planned early delivery versus expectant management (by condition)
Outcome: 1 Composite maternal mortality and morbidity
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestational hypertension
Broekhuijsen 2015 0/92 3/90 2.0 % 0.14 [ 0.01, 2.67 ]
Koopmans 2009 75/244 96/252 54.6 % 0.81 [ 0.63, 1.03 ]
Subtotal (95% CI) 336 342 56.7 % 0.78 [ 0.61, 1.00 ]
Total events: 75 (Delivery), 99 (Expectant)
Heterogeneity: Chi2 = 1.37, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 1.96 (P = 0.050)
2 Mild pre-eclampsia
Broekhuijsen 2015 2/165 4/159 2.4 % 0.48 [ 0.09, 2.59 ]
Koopmans 2009 41/123 67/123 38.7 % 0.61 [ 0.45, 0.82 ]
Subtotal (95% CI) 288 282 41.1 % 0.60 [ 0.45, 0.81 ]
Total events: 43 (Delivery), 71 (Expectant)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.34 (P = 0.00083)
3 Chronic hypertension
Broekhuijsen 2015 2/95 4/102 2.2 % 0.54 [ 0.10, 2.86 ]
Subtotal (95% CI) 95 102 2.2 % 0.54 [ 0.10, 2.86 ]
Total events: 2 (Delivery), 4 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Total (95% CI) 719 726 100.0 % 0.70 [ 0.58, 0.85 ]
Total events: 120 (Delivery), 174 (Expectant)
Heterogeneity: Chi2 = 3.49, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 3.68 (P = 0.00024)
Test for subgroup differences: Chi2 = 1.85, df = 2 (P = 0.40), I2 =0.0%
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Analysis 4.2. Comparison 4 Planned early delivery versus expectant management (by condition), Outcome
2 Respiratory distress syndrome.
Review: Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term
Comparison: 4 Planned early delivery versus expectant management (by condition)
Outcome: 2 Respiratory distress syndrome
Study or subgroup Delivery Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gestational hypertension
Broekhuijsen 2015 4/92 1/90 17.0 % 3.91 [ 0.45, 34.34 ]
Subtotal (95% CI) 92 90 17.0 % 3.91 [ 0.45, 34.34 ]
Total events: 4 (Delivery), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
2 Mild pre-eclampsia
Broekhuijsen 2015 10/165 2/159 34.3 % 4.82 [ 1.07, 21.65 ]
Subtotal (95% CI) 165 159 34.3 % 4.82 [ 1.07, 21.65 ]
Total events: 10 (Delivery), 2 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
3 Chronic hypertension
Broekhuijsen 2015 6/95 3/102 48.7 % 2.15 [ 0.55, 8.35 ]
Subtotal (95% CI) 95 102 48.7 % 2.15 [ 0.55, 8.35 ]
Total events: 6 (Delivery), 3 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 352 351 100.0 % 3.36 [ 1.36, 8.31 ]
Total events: 20 (Delivery), 6 (Expectant)
Heterogeneity: Chi2 = 0.66, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0086)
Test for subgroup differences: Chi2 = 0.65, df = 2 (P = 0.72), I2 =0.0%
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H I S T O R Y
Date Event Description
14 January 2014 Amended For clarification, the gestational age in the title has been changed from “at or near term” to “from
34 weeks to term”
12 December 2012 Amended This scope of this protocol has been expanded to incorporate all hypertensive disorders of pregnancy
and not just pre-eclampsia
The methods section (Assessment of reporting biases/Subgroup analysis and investigation of het-
erogeneity) has been updated to incorporate the Cochrane Pregnancy and Childbirth Groups’
updated standard methods text
A new co-author (C M Koopmans) has joined the review team.
C O N T R I B U T I O N S O F A U T H O R S
CC helped develop the protocol, extracted the data, checked data entry, helped write the review and is the guarantor for the review.
NN prepared the original protocol assisted and with the preparation of this review.
CK assisted with the preparation the protocol and review.
HW extracted the data, entered the data and helped write this review.
D E C L A R A T I O N S O F I N T E R E S T
CK is an author of an included study in this review (Koopmans 2009). All decisions relating to this study (assessment for inclusion/
exclusion, risk of bias and data extraction) were carried out by the other members of the review team who are not directly involved in
the study.
HW is paid to work on Cochrane reviews by a grant to Cochrane Pregnancy and Childbirth. The views and opinions expressed therein
are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department
of Health.
CC: none known.
NN: none known.
S O U R C E S O F S U P P O R T
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Internal sources
• (NN) Walter Sisulu Univeristy, East London Hospital Complex, South Africa.
NN was employed by East London Hospital Complex attached to Walter Sisulu University.
• (HW) Cochrane Pregnancy and Childbirth Group, Department of Women’s and Children’s Health, The University of
Liverpool, Liverpool, UK.
• (CC) Stellenbosch University, Cape Town, South Africa.
Cathy Cluver is registered for PhD at Stellenbosch University
External sources
• NIHR Cochrane Programme Grant Project: 13/89/05 - Pregnancy and childbirth systematic reviews to support clinical
guidelines, UK.
• (CC) Discovery Foundation, South Africa.
CC has been awarded the Discovery Accademic Fellowship
• (CC) South African Medical Association, South Africa.
CC has been awarded the SAMA Fellowship
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have edited the review title from ’Delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term’ to
’Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term’.
Our Types of studies and Types of interventions sections have been edited to incorporate ’planned early delivery’ as per the modified
title.
The methods have been updated to reflect current standard methods text of Cochrane Pregnancy and Childbirth and we have updated
some sections of the background.
We have used the GRADEpro Guideline Development Tool to assess the quality of the evidence included in this review. We have also
include a Summary of findings for the main comparison.
Respiratory distress syndrome was analysed by subgroup, in addition to the prespecified composite maternal and infant outcomes, as
the composite infant outcomes is not yet available by gestational age for Broekhuijsen 2015.
Changes to outcomes
Changes to maternal outcomes
We have made a number of changes to our protocol outcomes for maternal outcomes.
Primary outcome
The nature of the maternal composite outcome has been further clarified at the review stage:
• Protocol = Composite maternal outcome including maternal mortality (death during pregnancy or up to 42 days after end of
pregnancy) and severe morbidity (eclampsia, stroke, renal or liver failure as defined below), haemolysis, elevated liver enzymes and low
platelets syndrome (HELLP), disseminated intravascular coagulation (DIC), pulmonary oedema, thromboembolic disease, cardiac
arrest, abruption of the placenta or antepartum haemorrhage).
• Review = ’ Composite maternal outcome including maternal mortality (death during pregnancy or up to 42 days after delivery)
and severe morbidity (eclampsia, cerebral vascular event, pulmonary oedema as defined by trial authors, severe renal impairment
defined as a creatinine level greater than 125 µmol/l or a need for dialysis or urine output less than 0.5 mL/kg/hour for four hours
unresponsive to hydration with two intravenous boluses, or as defined by trial authors, liver haematoma or rupture, liver failure
defined as the rapid impairment of synthetic function and development of encephalopathy or as defined by trial authors, haemolysis
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elevated liver enzymes and low platelets (HELLP) syndrome, disseminated intravascular coagulation (DIC), thromboembolic disease
and abruptio placentae defined as a retroplacental clot of more than 15% of the maternal surface or as defined by trial authors.
Secondary outcomes
Our secondary outcomes edited accordingly:
• ’Death as defined above’ has been edited to ’Maternal mortality as described above’
• ’Eclampsia (fitting)’ has been edited to ’Eclampsia’
• Stroke (brain damage) has been edited to ’Cerebrovascular event’
• ’Pulmonary oedema (fluid in the lungs)’ has been edited to ’Pulmonary oedema’
• ’Kidney failure (defined as rise in serum creatine concentration by > 1 mg/dL over baseline) and/or urine output less than 0.5
mL/kg/hr for two hours unresponsive to hydration with two intravenous boluses of 500 mL fluid), or as defined by trial authors’ has
been edited to ’Severe renal impairment as defined above’
• ’Liver failure (the rapid impairment of synthetic function and development of encephalopathy) or as defined by trial authors’ has
been edited to ’Liver failure as defined above’
• ’Abruption of the placenta or antepartum haemorrhage’ has been split into two separate outcomes, ’Abruptio placentae’ and
’Antepartum haemorrhage’
• ’Postpartum haemorrhage (blood loss 500 mL or more’ has been edited to ’Postpartum haemorrhage (blood loss of more than
500 mL within 24 hours of delivery’
The following secondary outcomes have been added at the review stage:
• ’Liver haematoma or rupture’
• ’Admission to a high care or intensive care unit’
Changes to fetal/neonatal outcomes
We have made a number of changes to our protocol outcomes for fetal/neonatal outcomes:
Primary outcome
The nature of the perinatal composite outcome has been further clarified at the review stage:
• Protocol = Composite perinatal outcome (perinatal death (stillbirth or death in the first seven days of life), small-for-gestational
age (growth below the third centile or lowest centile reported), acute respiratory distress syndrome (ARDS), necrotising enterocolitis
(NEC), cerebral haemorrhage, Apgar score less than seven or very low (less than four) at five minutes, cord blood pH less than 7.1,
neonatal seizures, intraventricular haemorrhage)
• Review = ’Composite perinatal outcome including fetal or neonatal death (within six weeks after the expected due date or as
defined by trial authors), grade III or IV intraventricular or intracerebral haemorrhage, necrotising enterocolitis (NEC), acute
respiratory distress syndrome (ARDS) or grade III/IV hyaline membrane disease, small-for-gestational age (growth below the 10th
centile or as defined by trial authors) and neonatal seizures.
Secondary outcomes
Our secondary outcomes edited accordingly:
• ’Stillbirth’, ’perinatal death’ and ’neonatal death’ have been replaced with ’fetal death’, neonatal death (as defined in the primary
outcome above).
• ’Intraventricular haemorrhage’ has been edited to ’Grade III or IV intraventricular or intracerebral haemorrhage’.
• ’ARDS’ has been edited to ’ARDS or grade III/IV hyaline membrane disease’
• The outcome ’small-for-gestational age’ was changed to ’small-for-gestational age as defined by trial authors’, with definitions
given in the footnotes of the data
• ’Apgar score at five minutes: low (less than seven), very low (less than four) or lowest reported’ has been replaced with ’Apgar
score less than seven at five minutes’
• ’Cord blood pH less than 7.1’ has been edited to ’Cord blood pH less than 7.1 or as defined by the trial authors’
• ’Endotracheal intubation or use of mechanical ventilation’ has been edited to ’Intubation and mechanical ventilation or
continuous positive airway pressure support’
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The following secondary outcomes have been added at the review stage:
• ’Early neonatal sepsis’
• ’Surfactant use’
• ’Neonatal intensive care unit use or high care unit admission’
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Cesarean Section [statistics & numerical data]; ∗Hypertension; ∗Labor, Induced [statistics & numerical data]; ∗Pregnancy Complica-
tions, Cardiovascular; ∗Watchful Waiting; Delivery, Obstetric; Gestational Age; Infant Mortality; Length of Stay; Maternal Mortality;
Pre-Eclampsia; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Infant; Infant, Newborn; Pregnancy
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